Skip to content

A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

A NATURAL HISTORY STUDY IN CHINESE MALE PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03760029
Enrollment
312
Registered
2018-11-30
Start date
2019-07-24
Completion date
2023-03-21
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Brief summary

This is a multicenter, prospective, single cohort study designed to describe the natural history of DMD in Chinese male patients. A total of approximately 330 subjects will be enrolled with the target number of subjects in each group as below: * Group 1, Ambulatory subjects aged \<6 years, approximately 100 subjects; * Group 2, Ambulatory subjects aged \>=6 years, approximately 180 subjects; * Group 3, Non-ambulatory subjects, approximately 50 subjects. Subjects will visit sites every 6 months. Each subject will be observed for at least 24 months. All subjects will remain enrolled until the study completion date, such that some will have data collected after Month 24. Subjects, who complete Visit 5/Month 24 at least 6 months prior to study completion, will be asked to complete an additional visit at Month 30.

Interventions

All subjects need to visit sites more frequently than in routine clinical practice.

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor). 2. Subjects who are \>=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (\<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged \>4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators.

Exclusion criteria

1. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date. 2. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases. 3. Subjects \>=4 years old who have not completed the varicella vaccination. 4. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 YearsBaseline (Day 1) and Month 24WISC-IV is an individually administered intelligence test for children between the ages of 6 and 16. The WISC-IV Composites are: Verbal Comprehension, Perceptual Reasoning, Working Memory, and Processing Speed. Scores from the Composites constitute the WISC-IV Full Scale IQ score which ranges from 40 (Exceptionally Low) to 160 (Exceptionally Superior), higher scores indicated more intelligence. The WISC was only performed in ambulatory participants \>= 6 to \<=16 years old as pre-specified in the protocol.
Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in %pFVC at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.
Change From Baseline in %pFVC at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.
Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 12FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 24FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 30FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12Forced expiratory volume in one second (FEV1) is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 12FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 24FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 30FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.
Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 12The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 24The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 30The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in LVEF at Month 24: Participants Aged >=6 YearsBaseline (Day 1) and Month 24LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in LVEF at Month 30: Participants Aged >=6 YearsBaseline (Day 1) and Month 30LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.
Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 12LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 24LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)Baseline (Day 1) and Month 30LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.
Age of Participants When They Failed to WalkUp to Month 30Participant's age at life-altering clinical milestones- failure to walk was calculated based on the birthdate and the date of failure to walk as reported by caregiver during 30 months of this study. Participants who were not reported being failure to walk by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.
Age of Participants When They Failed to StandUp to Month 30Participant's age at life-altering clinical milestones- failure to stand was calculated based on the birthdate and the date of failure to stand as reported by caregiver during 30 months of this study. Participants who were not reported being failure to stand by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.
Age of Participants When They Failed to Self-feedUp to Month 30Participant's age at life-altering clinical milestones- failure to self-feed during 30 months of this study was analyzed using the Kaplan-Meier method. Age was summarized in years.
Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 6NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (example \[e.g.\] standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 12NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 18NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 24NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 30NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.
Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 YearsBaseline (Day 1) and Month 6PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 YearsBaseline (Day 1) and Month 12PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 YearsBaseline (Day 1) and Month 18PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 YearsBaseline (Day 1) and Month 24PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 YearsBaseline (Day 1) and Month 30PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.
Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years OnlyBaseline (Day 1) and Month 6The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years OnlyBaseline (Day 1) and Month 12The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years OnlyBaseline (Day 1) and Month 18The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years OnlyBaseline (Day 1) and Month 24The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years OnlyBaseline (Day 1) and Month 30The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.
Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 6The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 12The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 18The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 24The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 YearsBaseline (Day 1) and Month 30The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.
Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsBaseline (Day 1) and Month 6Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsBaseline (Day 1) and Month 12Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsBaseline (Day 1) and Month 18Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsBaseline (Day 1) and Month 24Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsBaseline (Day 1) and Month 30Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsBaseline (Day 1) and Month 6Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsBaseline (Day 1) and Month 12Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsBaseline (Day 1) and Month 18Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsBaseline (Day 1) and Month 24Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsBaseline (Day 1) and Month 30Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsBaseline (Day 1) and Month 6Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsBaseline (Day 1) and Month 12Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsBaseline (Day 1) and Month 18Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsBaseline (Day 1) and Month 24Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsBaseline (Day 1) and Month 30Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsBaseline (Day 1) and Month 6Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsBaseline (Day 1) and Month 12Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsBaseline (Day 1) and Month 18Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsBaseline (Day 1) and Month 24Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsBaseline (Day 1) and Month 30Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.
Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Baseline (Day 1) and Month 6Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Change From Baseline in ROM at Bilateral Ankles at Month 12Baseline (Day 1) and Month 12Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Change From Baseline in ROM at Bilateral Ankles at Month 18Baseline (Day 1) and Month 18Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Change From Baseline in ROM at Bilateral Ankles at Month 24Baseline (Day 1) and Month 24Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Change From Baseline in ROM at Bilateral Ankles at Month 30Baseline (Day 1) and Month 30Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.
Change From Baseline in ROM at Bilateral Elbows at Month 6Baseline (Day 1) and Month 6Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Change From Baseline in ROM at Bilateral Elbows at Month 12Baseline (Day 1) and Month 12Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Change From Baseline in ROM at Bilateral Elbows at Month 18Baseline (Day 1) and Month 18Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Change From Baseline in ROM at Bilateral Elbows at Month 24Baseline (Day 1) and Month 24Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Change From Baseline in ROM at Bilateral Elbows at Month 30Baseline (Day 1) and Month 30Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.
Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 YearsBaseline (Day 1) and Month 12Forced vital capacity (FVC) is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.

Secondary

MeasureTime frameDescription
Number of Participants With Each Affected Exon by Mutation TypesUp to Month 30Number of participants with each affected exon by mutation types is presented in this outcome measure. Only those categories with non-zero values have been reported.
Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Up to Month 30Number of participants with DMD mutations affecting any exon between exon 9 and exon 13 or deletion that affects both exon 29 and exon 30 is presented in this outcome measure.
Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Baseline (Day 1) and Months 6, 12, 18, 24 and 30The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Baseline (Day 1) and Months 6, 12, 18, 24 and 30The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Baseline (Day 1) and Months 6, 12, 18, 24 and 30The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.
Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Months 12EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Month 24EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Month 30EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.
Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Baseline (Day 1) and Months 12, 24 and 30EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), where higher scores indicated better quality of life. EQ-VAS assessment was only performed in the participants \>= 16 years old.
Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Baseline (Day 1) and Months 12, 24, and 30EQ-5D-3L index score, participants rated their current health state on 5 single-item dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with each dimension having three levels of severity: 1=no problems, 2=some problems and 3=extreme problems. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total index score range of 0 to 1.00. Higher scores indicating a better quality of life. EQ-5D-3L was only performed in participants \>= 16 years old.
Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Month 12EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Month 24EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Month 30EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.
Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<=16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where, -0.109= the worst health status, 1= full health. Higher the score the better the better quality of life.
Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to their child's use of healthcare professionals, emergency room visits, and hospitalizations in past 3 months. Change from baseline in mean number of visits to primary care physician, emergency room and office visits is presented in this outcome measure.
Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to number of nights in hospital due to disease/dedication for disease in past 3 months. Change from baseline in mean number of nights in hospital due to disease or medication for disease is presented in this outcome measure.
Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Baseline (Day 1) and Months 12, 24, and 30Caregivers were asked to estimate out-of-pocket costs related to healthcare resource utilization. The number of out of pocket money was defined as the total spent of the past three months in managing child's Duchenne muscular dystrophy.
Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12Baseline (Day 1) and Month 12WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24Baseline (Day 1) and Month 24WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30Baseline (Day 1) and Month 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Baseline (Day 1) and Months 12, 24, and 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Months 12, 24, and 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Percent Work Time Missed Score as Per WPAI: CG at Month 12Month 12WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Percent Work Time Missed Score as Per WPAI: CG at Month 24Month 24WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Percent Work Time Missed Score as Per WPAI: CG at Month 30Month 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Months 12, 24, and 30WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.
Number of Participants With Type of DMD MutationUp to Month 30Number of participants as per type of mutation: exon deletion, exon duplication, point mutation, small insertion, small deletion and others is presented in this outcome measure. One participant could have more than 1 mutation type.

Countries

China

Participant flow

Recruitment details

This was a multicenter, prospective study to describe natural history of Duchenne muscular dystrophy (DMD) in Chinese male participants.

Pre-assignment details

A total of 318 participants were screened of which 6 were screen failures and 312 participants were enrolled at 6 sites in China.

Participants by arm

ArmCount
Ambulatory Participants With Age <6 Years
Participants diagnosed with DMD who were ambulant and were less than 6 years of age at the time of screening were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the standard of care (SOC).
99
Ambulatory Participants With Age >=6 Years
Participants diagnosed with DMD who were ambulant and were greater than or equal to (\>=6) years of age at the time of screening were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the SOC.
177
Non-ambulatory Participants
Participants diagnosed with DMD who were non-ambulatory (i.e., used wheel chair full-time or were unable to complete daily activities \[such as going to bathroom\] by walking independently, based on performance reported at home by participant or caregiver and verification by trained clinical evaluator \[CE\] with the inability to perform the 10-meter run/walk assessment) were included. No investigational drug was administered, and participants were allowed to take medications prescribed by their physicians, which constituted the SOC.
36
Total312

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyDeath100
Overall StudyLost to Follow-up021
Overall StudyOther210
Overall StudyWithdrawal by parent/guardian441
Overall StudyWithdrawal by Subject141

Baseline characteristics

CharacteristicTotalAmbulatory Participants With Age <6 YearsAmbulatory Participants With Age >=6 YearsNon-ambulatory Participants
Age, Continuous7.9 Years
STANDARD_DEVIATION 3.43
4.0 Years
STANDARD_DEVIATION 1.23
9.0 Years
STANDARD_DEVIATION 1.99
12.7 Years
STANDARD_DEVIATION 2.71
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
312 Participants99 Participants177 Participants36 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
312 Participants99 Participants177 Participants36 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Male
312 Participants99 Participants177 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
1 / 990 / 1770 / 36
other
Total, other adverse events
84 / 99136 / 17720 / 36
serious
Total, serious adverse events
0 / 990 / 1770 / 36

Outcome results

Primary

Age of Participants When They Failed to Self-feed

Participant's age at life-altering clinical milestones- failure to self-feed during 30 months of this study was analyzed using the Kaplan-Meier method. Age was summarized in years.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \<6 years and \>=6 years had an event of failure to self-feed.

ArmMeasureValue (MEDIAN)
Ambulatory Participants With Age <6 YearsAge of Participants When They Failed to Self-feedNA Years
Ambulatory Participants With Age >=6 YearsAge of Participants When They Failed to Self-feedNA Years
Total Ambulatory ParticipantsAge of Participants When They Failed to Self-feedNA Years
Non-ambulatory ParticipantsAge of Participants When They Failed to Self-feed20.0 Years
Total ParticipantsAge of Participants When They Failed to Self-feed20.0 Years
Primary

Age of Participants When They Failed to Stand

Participant's age at life-altering clinical milestones- failure to stand was calculated based on the birthdate and the date of failure to stand as reported by caregiver during 30 months of this study. Participants who were not reported being failure to stand by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \<6 years had an event of failure to stand.

ArmMeasureValue (MEDIAN)
Ambulatory Participants With Age <6 YearsAge of Participants When They Failed to StandNA Years
Ambulatory Participants With Age >=6 YearsAge of Participants When They Failed to Stand14.4 Years
Total Ambulatory ParticipantsAge of Participants When They Failed to Stand14.4 Years
Non-ambulatory ParticipantsAge of Participants When They Failed to Stand11.0 Years
Total ParticipantsAge of Participants When They Failed to Stand13.1 Years
Primary

Age of Participants When They Failed to Walk

Participant's age at life-altering clinical milestones- failure to walk was calculated based on the birthdate and the date of failure to walk as reported by caregiver during 30 months of this study. Participants who were not reported being failure to walk by their caregivers were censored on the day of their last visit. Kaplan-Meier method was used for analysis.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, 'Number of Participants Analyzed' signifies participants included in the Kaplan-Meier analysis. No participant in Ambulatory participants aged \< 6 years had an event of failure to walk.

ArmMeasureValue (MEDIAN)
Ambulatory Participants With Age <6 YearsAge of Participants When They Failed to WalkNA Years
Ambulatory Participants With Age >=6 YearsAge of Participants When They Failed to Walk14.4 Years
Total Ambulatory ParticipantsAge of Participants When They Failed to Walk14.4 Years
Non-ambulatory ParticipantsAge of Participants When They Failed to Walk11.1 Years
Total ParticipantsAge of Participants When They Failed to Walk13.1 Years
Primary

Change From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years

The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years0.3 Meters per secondStandard Deviation 0.35
Ambulatory Participants With Age >=6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years-0.1 Meters per secondStandard Deviation 0.34
Total Ambulatory ParticipantsChange From Baseline in 10 Meter Walk or Run Velocity at Month 12: Ambulatory Participants Aged >=3 Years-0.0 Meters per secondStandard Deviation 0.4
Primary

Change From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years

The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years0.4 Meters per secondStandard Deviation 0.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years-0.3 Meters per secondStandard Deviation 0.34
Total Ambulatory ParticipantsChange From Baseline in 10 Meter Walk or Run Velocity at Month 18: Ambulatory Participants Aged >=3 Years-0.0 Meters per secondStandard Deviation 0.5
Primary

Change From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years

The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years0.5 Meters per secondStandard Deviation 0.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years-0.4 Meters per secondStandard Deviation 0.39
Total Ambulatory ParticipantsChange From Baseline in 10 Meter Walk or Run Velocity at Month 24: Ambulatory Participants Aged >=3 Years-0.1 Meters per secondStandard Deviation 0.56
Primary

Change From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years

The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years0.4 Meters per secondStandard Deviation 0.52
Ambulatory Participants With Age >=6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years-0.6 Meters per secondStandard Deviation 0.44
Total Ambulatory ParticipantsChange From Baseline in 10 Meter Walk or Run Velocity at Month 30: Ambulatory Participants Aged >=3 Years-0.3 Meters per secondStandard Deviation 0.62
Primary

Change From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years

The 10 meter walk or run test was performed as part of NSAA. The 10 meter walk or run velocity was defined as the reciprocal of the time (in seconds) to complete the 10 meter run or walk test. The 10 meter walk or run test was performed in ambulatory children \>=3 years old only as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years0.2 Meters per secondStandard Deviation 0.42
Ambulatory Participants With Age >=6 YearsChange From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years-0.1 Meters per secondStandard Deviation 0.27
Total Ambulatory ParticipantsChange From Baseline in 10 Meter Walk or Run Velocity at Month 6: Ambulatory Participants Aged >=3 Years0.0 Meters per secondStandard Deviation 0.35
Primary

Change From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.74
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Extension0.4 KilogramsStandard Deviation 0.88
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.87
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.97
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.85
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.96
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 0.76
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Extension0.0 KilogramsStandard Deviation 0.68
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.83
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.93
Primary

Change From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Extension0.6 KilogramsStandard Deviation 0.8
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Extension-0.0 KilogramsStandard Deviation 0.84
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 1
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 1.09
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.99
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 1.06
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Extension-0.2 KilogramsStandard Deviation 0.13
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Extension-0.4 KilogramsStandard Deviation 0.73
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.98
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 1.04
Primary

Change From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Extension1.1 KilogramsStandard Deviation 1.14
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Extension0.7 KilogramsStandard Deviation 1.29
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Extension0.1 KilogramsStandard Deviation 1.03
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Extension0.0 KilogramsStandard Deviation 1.09
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Extension0.3 KilogramsStandard Deviation 1.08
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Extension0.1 KilogramsStandard Deviation 1.13
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.96
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Extension-0.1 KilogramsStandard Deviation 0.73
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 1.05
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Extension0.1 KilogramsStandard Deviation 1.11
Primary

Change From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Extension0.8 KilogramsStandard Deviation 1.55
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Extension-0.9 KilogramsStandard Deviation 0.72
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 1.3
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 1.37
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Extension0.3 KilogramsStandard Deviation 1.32
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 1.36
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Extension-0.0 KilogramsStandard Deviation 0.37
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Extension-0.3 KilogramsStandard Deviation 0.79
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Extension0.3 KilogramsStandard Deviation 1.3
Total ParticipantsChange From Baseline in Elbow Extension Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Extension0.2 KilogramsStandard Deviation 1.33
Primary

Change From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow extension were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Extension0.4 KilogramsStandard Deviation 0.85
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 1.22
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.78
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.87
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.79
Total Ambulatory ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.92
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Extension0.1 KilogramsStandard Deviation 0.26
Non-ambulatory ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Extension0.1 KilogramsStandard Deviation 0.21
Total ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Extension0.2 KilogramsStandard Deviation 0.78
Total ParticipantsChange From Baseline in Elbow Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Extension0.3 KilogramsStandard Deviation 0.91
Primary

Change From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Flexion0.5 KilogramsStandard Deviation 0.97
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Flexion0.5 KilogramsStandard Deviation 0.79
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Flexion0.1 KilogramsStandard Deviation 1.02
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Flexion0.2 KilogramsStandard Deviation 1.07
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.02
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Flexion0.3 KilogramsStandard Deviation 1.05
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Flexion-0.1 KilogramsStandard Deviation 0.89
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Flexion0.1 KilogramsStandard Deviation 1.12
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Elbow Flexion0.1 KilogramsStandard Deviation 1.03
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Elbow Flexion0.2 KilogramsStandard Deviation 1.03
Primary

Change From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Flexion0.7 KilogramsStandard Deviation 0.8
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Flexion0.5 KilogramsStandard Deviation 0.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.14
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Flexion0.2 KilogramsStandard Deviation 1.16
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.11
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Flexion0.3 KilogramsStandard Deviation 1.12
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Flexion-0.9 KilogramsStandard Deviation 1.35
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Flexion-1.0 KilogramsStandard Deviation 0.83
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.12
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Elbow Flexion0.2 KilogramsStandard Deviation 1.13
Primary

Change From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Flexion0.8 KilogramsStandard Deviation 0.89
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Flexion0.9 KilogramsStandard Deviation 0.81
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Flexion0.0 KilogramsStandard Deviation 1.18
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Flexion0.1 KilogramsStandard Deviation 1.16
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Flexion0.1 KilogramsStandard Deviation 1.17
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Flexion0.2 KilogramsStandard Deviation 1.15
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Flexion-0.3 KilogramsStandard Deviation 1.15
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Flexion-0.0 KilogramsStandard Deviation 0.92
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Elbow Flexion0.1 KilogramsStandard Deviation 1.14
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Elbow Flexion0.1 KilogramsStandard Deviation 1.16
Primary

Change From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Flexion0.8 KilogramsStandard Deviation 0.72
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Flexion0.4 KilogramsStandard Deviation 0.7
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.58
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Flexion0.4 KilogramsStandard Deviation 1.56
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.53
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Flexion0.4 KilogramsStandard Deviation 1.5
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Flexion-0.0 KilogramsStandard Deviation 0.68
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Flexion-0.0 KilogramsStandard Deviation 0.83
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Elbow Flexion0.2 KilogramsStandard Deviation 1.51
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Elbow Flexion0.4 KilogramsStandard Deviation 1.47
Primary

Change From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right elbow flexion were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Flexion0.3 KilogramsStandard Deviation 0.85
Ambulatory Participants With Age <6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Flexion0.4 KilogramsStandard Deviation 0.81
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Flexion0.3 KilogramsStandard Deviation 0.93
Ambulatory Participants With Age >=6 YearsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Flexion0.3 KilogramsStandard Deviation 0.93
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Flexion0.3 KilogramsStandard Deviation 0.92
Total Ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Flexion0.3 KilogramsStandard Deviation 0.91
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Flexion-0.3 KilogramsStandard Deviation 0.25
Non-ambulatory ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Flexion-0.4 KilogramsStandard Deviation 0.3
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Elbow Flexion0.3 KilogramsStandard Deviation 0.92
Total ParticipantsChange From Baseline in Elbow Flexion of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Elbow Flexion0.3 KilogramsStandard Deviation 0.91
Primary

Change From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Knee Extension-0.1 KilogramsStandard Deviation 1.25
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Knee Extension0.1 KilogramsStandard Deviation 1.5
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Knee Extension-0.1 KilogramsStandard Deviation 1.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Knee Extension-0.4 KilogramsStandard Deviation 1.87
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Knee Extension-0.1 KilogramsStandard Deviation 1.8
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Knee Extension-0.4 KilogramsStandard Deviation 1.84
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Knee Extension-0.3 KilogramsStandard Deviation 1.1
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Knee Extension-0.3 KilogramsStandard Deviation 1.31
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Knee Extension-0.1 KilogramsStandard Deviation 1.74
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Knee Extension-0.4 KilogramsStandard Deviation 1.75
Primary

Change From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Knee Extension0.7 KilogramsStandard Deviation 1.69
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Knee Extension0.5 KilogramsStandard Deviation 1.96
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Knee Extension-0.4 KilogramsStandard Deviation 1.95
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Knee Extension-0.7 KilogramsStandard Deviation 2.29
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Knee Extension-0.3 KilogramsStandard Deviation 1.95
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Knee Extension-0.6 KilogramsStandard Deviation 2.28
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Knee Extension-0.8 KilogramsStandard Deviation 0.42
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Knee Extension-0.7 KilogramsStandard Deviation 1.05
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Knee Extension-0.3 KilogramsStandard Deviation 1.93
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Knee Extension-0.6 KilogramsStandard Deviation 2.25
Primary

Change From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Knee Extension-0.4 KilogramsStandard Deviation 2.37
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Knee Extension0.0 KilogramsStandard Deviation 2.77
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Knee Extension-0.6 KilogramsStandard Deviation 1.95
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Knee Extension-1.0 KilogramsStandard Deviation 2.13
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Knee Extension-0.6 KilogramsStandard Deviation 2
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Knee Extension-0.9 KilogramsStandard Deviation 2.23
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Knee Extension-0.7 KilogramsStandard Deviation 1.62
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Knee Extension-0.5 KilogramsStandard Deviation 1.64
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Knee Extension-0.6 KilogramsStandard Deviation 1.95
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Knee Extension-0.8 KilogramsStandard Deviation 2.16
Primary

Change From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Knee Extension-0.9 KilogramsStandard Deviation 2.12
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Knee Extension-2.3 KilogramsStandard Deviation 2.89
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Knee Extension-0.7 KilogramsStandard Deviation 2.66
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Knee Extension-1.4 KilogramsStandard Deviation 2.76
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Knee Extension-0.7 KilogramsStandard Deviation 2.6
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Knee Extension-1.4 KilogramsStandard Deviation 2.76
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Knee Extension-1.1 KilogramsStandard Deviation 0.44
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Knee Extension-0.4 KilogramsStandard Deviation 0.36
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Knee Extension-0.7 KilogramsStandard Deviation 2.56
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Knee Extension-1.4 KilogramsStandard Deviation 2.72
Primary

Change From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right knee extension was analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Knee Extension0.5 KilogramsStandard Deviation 1.91
Ambulatory Participants With Age <6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Knee Extension0.7 KilogramsStandard Deviation 2.35
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Knee Extension0.0 KilogramsStandard Deviation 1.43
Ambulatory Participants With Age >=6 YearsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Knee Extension-0.1 KilogramsStandard Deviation 1.78
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Knee Extension0.1 KilogramsStandard Deviation 1.5
Total Ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Knee Extension0.0 KilogramsStandard Deviation 1.87
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Knee Extension-0.0 KilogramsStandard Deviation 0.37
Non-ambulatory ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Knee Extension0.3 KilogramsStandard Deviation 0.29
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Knee Extension0.1 KilogramsStandard Deviation 1.49
Total ParticipantsChange From Baseline in Knee Extension of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Knee Extension0.0 KilogramsStandard Deviation 1.85
Primary

Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years4.1 Percentage of ejected bloodStandard Deviation 45.37
Ambulatory Participants With Age >=6 YearsChange From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years-0.4 Percentage of ejected bloodStandard Deviation 6.32
Total Ambulatory ParticipantsChange From Baseline in Left Ventricular Ejection Fraction (LVEF) at Month 12: Participants Aged >=6 Years3.4 Percentage of ejected bloodStandard Deviation 41.83
Primary

Change From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)0.5 Percentage of ejected bloodStandard Deviation 6.27
Ambulatory Participants With Age >=6 YearsChange From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-0.4 Percentage of ejected bloodStandard Deviation 6.32
Total Ambulatory ParticipantsChange From Baseline in LVEF at Month 12: Participants Aged >=6 Years (Unplanned Analysis)0.4 Percentage of ejected bloodStandard Deviation 6.27
Primary

Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years-0.7 Percentage of ejected bloodStandard Deviation 5.43
Ambulatory Participants With Age >=6 YearsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years-1.6 Percentage of ejected bloodStandard Deviation 7.58
Total Ambulatory ParticipantsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years-0.8 Percentage of ejected bloodStandard Deviation 5.78
Primary

Change From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-0.7 Percentage of ejected bloodStandard Deviation 5.43
Ambulatory Participants With Age >=6 YearsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-1.6 Percentage of ejected bloodStandard Deviation 7.58
Total Ambulatory ParticipantsChange From Baseline in LVEF at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-0.8 Percentage of ejected bloodStandard Deviation 5.78
Primary

Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years-0.3 Percentage of ejected bloodStandard Deviation 6.42
Ambulatory Participants With Age >=6 YearsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years-2.0 Percentage of ejected bloodStandard Deviation 4.69
Total Ambulatory ParticipantsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years-0.4 Percentage of ejected bloodStandard Deviation 6.34
Primary

Change From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)

LVEF was the percentage of blood that was ejected out of left ventricle with each contraction, estimated by echocardiography. The LVEF was only performed in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-0.3 Percentage of ejected bloodStandard Deviation 6.42
Ambulatory Participants With Age >=6 YearsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-2.0 Percentage of ejected bloodStandard Deviation 4.69
Total Ambulatory ParticipantsChange From Baseline in LVEF at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-0.4 Percentage of ejected bloodStandard Deviation 6.34
Primary

Change From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years1.0 Centimeter of water (cm H2O)Standard Deviation 14.72
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years-5.5 Centimeter of water (cm H2O)Standard Deviation 14.24
Total Ambulatory ParticipantsChange From Baseline in Maximum Expiratory Pressure at Month 12: Participants Aged >=6 Years-0.0 Centimeter of water (cm H2O)Standard Deviation 14.8
Primary

Change From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years0.6 Centimeter of water (cm H2O)Standard Deviation 18.07
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years-2.5 Centimeter of water (cm H2O)Standard Deviation 13.67
Total Ambulatory ParticipantsChange From Baseline in Maximum Expiratory Pressure at Month 24: Participants Aged >=6 Years0.1 Centimeter of water (cm H2O)Standard Deviation 17.48
Primary

Change From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in SAP.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years1.7 Centimeter of water (cm H2O)Standard Deviation 17.91
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years-20.3 Centimeter of water (cm H2O)Standard Deviation 23.61
Total Ambulatory ParticipantsChange From Baseline in Maximum Expiratory Pressure at Month 30: Participants Aged >=6 Years0.6 Centimeter of water (cm H2O)Standard Deviation 18.68
Primary

Change From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years1.4 Centimeter of water (cm H2O)Standard Deviation 18.22
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years-3.1 Centimeter of water (cm H2O)Standard Deviation 20.46
Total Ambulatory ParticipantsChange From Baseline in Maximum Inspiratory Pressure at Month 12: Participants Aged >=6 Years0.6 Centimeter of water (cm H2O)Standard Deviation 18.62
Primary

Change From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years0.9 Centimeter of water (cm H2O)Standard Deviation 18.24
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years-2.8 Centimeter of water (cm H2O)Standard Deviation 17.24
Total Ambulatory ParticipantsChange From Baseline in Maximum Inspiratory Pressure at Month 24: Participants Aged >=6 Years0.3 Centimeter of water (cm H2O)Standard Deviation 18.08
Primary

Change From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years2.5 Centimeter of water (cm H2O)Standard Deviation 19.19
Ambulatory Participants With Age >=6 YearsChange From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years-14.0 Centimeter of water (cm H2O)Standard Deviation 13.22
Total Ambulatory ParticipantsChange From Baseline in Maximum Inspiratory Pressure at Month 30: Participants Aged >=6 Years1.6 Centimeter of water (cm H2O)Standard Deviation 19.22
Primary

Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years

NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (example \[e.g.\] standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years1.3 Units on a scaleStandard Deviation 4.44
Ambulatory Participants With Age >=6 YearsChange From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years-1.0 Units on a scaleStandard Deviation 3.98
Total Ambulatory ParticipantsChange From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6: Ambulatory Participants Aged >=3 Years-0.3 Units on a scaleStandard Deviation 4.24
Primary

Change From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years

NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years2.7 Units on a scaleStandard Deviation 5.37
Ambulatory Participants With Age >=6 YearsChange From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years-2.1 Units on a scaleStandard Deviation 4.88
Total Ambulatory ParticipantsChange From Baseline in NSAA Total Score at Month 12: Ambulatory Participants Aged >=3 Years-0.9 Units on a scaleStandard Deviation 5.42
Primary

Change From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years

NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years4.1 Units on a scaleStandard Deviation 5.12
Ambulatory Participants With Age >=6 YearsChange From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years-3.6 Units on a scaleStandard Deviation 4.53
Total Ambulatory ParticipantsChange From Baseline in NSAA Total Score at Month 18: Ambulatory Participants Aged >=3 Years-1.2 Units on a scaleStandard Deviation 5.93
Primary

Change From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years

NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years3.9 Units on a scaleStandard Deviation 4.67
Ambulatory Participants With Age >=6 YearsChange From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years-4.9 Units on a scaleStandard Deviation 5.22
Total Ambulatory ParticipantsChange From Baseline in NSAA Total Score at Month 24: Ambulatory Participants Aged >=3 Years-2.1 Units on a scaleStandard Deviation 6.5
Primary

Change From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years

NSAA is a 17-item test that grades performance of various functional skills using the following scale: 0 (unable to achieve goal independently), 1 (modified method but achieves goal with no physical assistance), or 2 (normal- no obvious modification of activity). The scale assesses activities required to remain functionally ambulant (e.g. rise from the floor), activities that can be difficult even early in the disease (e.g. standing on heels) and activities that are known to progressively deteriorate over time (stand from a chair, walk). NSAA total score was calculated by adding the responses of all 17 items and ranged from 0 to 34, with higher scores indicating better function. NSAA was only performed in ambulatory participants aged \>=3 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years4.1 Units on a scaleStandard Deviation 5.09
Ambulatory Participants With Age >=6 YearsChange From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years-5.9 Units on a scaleStandard Deviation 5.56
Total Ambulatory ParticipantsChange From Baseline in NSAA Total Score at Month 30: Ambulatory Participants Aged >=3 Years-3.6 Units on a scaleStandard Deviation 6.84
Primary

Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years14.0 Liters per minuteStandard Deviation 46.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years38.6 Liters per minuteStandard Deviation 61.5
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years17.9 Liters per minuteStandard Deviation 49.94
Primary

Change From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)14.0 Liters per minuteStandard Deviation 46.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)38.6 Liters per minuteStandard Deviation 61.5
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 12: Participants Aged >=6 Years (Unplanned Analysis)17.9 Liters per minuteStandard Deviation 49.94
Primary

Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years20.7 Liters per minuteStandard Deviation 59.04
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years46.1 Liters per minuteStandard Deviation 67.78
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years24.4 Liters per minuteStandard Deviation 60.84
Primary

Change From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)22.4 Liters per minuteStandard Deviation 55.94
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)46.1 Liters per minuteStandard Deviation 67.78
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 24: Participants Aged >=6 Years (Unplanned Analysis)25.9 Liters per minuteStandard Deviation 58.22
Primary

Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years25.2 Liters per minuteStandard Deviation 62.83
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years74.0 Liters per minuteStandard Deviation 24.84
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years27.7 Liters per minuteStandard Deviation 62.32
Primary

Change From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)

The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)25.2 Liters per minuteStandard Deviation 62.83
Ambulatory Participants With Age >=6 YearsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)74.0 Liters per minuteStandard Deviation 24.84
Total Ambulatory ParticipantsChange From Baseline in Peak Cough Flow at Month 30: Participants Aged >=6 Years (Unplanned Analysis)27.7 Liters per minuteStandard Deviation 62.32
Primary

Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years

Forced expiratory volume in one second (FEV1) is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years-1.8 Percent predicted FEV1Standard Deviation 18.65
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years-4.0 Percent predicted FEV1Standard Deviation 19.64
Total Ambulatory ParticipantsChange From Baseline in Percent Predicted Forced Expiratory Volume in One Second (%pFEV1) at Month 12: Participants Aged >=6 Years-2.1 Percent predicted FEV1Standard Deviation 18.78
Primary

Change From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years

Forced vital capacity (FVC) is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years-2.9 Percent predicted FVCStandard Deviation 15.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years-5.7 Percent predicted FVCStandard Deviation 19.79
Total Ambulatory ParticipantsChange From Baseline in Percent Predicted Forced Vital Capacity (%pFVC) at Month 12: Participants Aged >=6 Years-3.4 Percent predicted FVCStandard Deviation 16.52
Primary

Change From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years-0.0 Units on a scaleStandard Deviation 2.33
Ambulatory Participants With Age >=6 YearsChange From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years-0.8 Units on a scaleStandard Deviation 2.22
Total Ambulatory ParticipantsChange From Baseline in Performance of Upper Limb (PUL) 2.0 Total Score at Month 6: Participants Aged >=10 Years-0.1 Units on a scaleStandard Deviation 2.31
Primary

Change From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)

FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-1.8 Percent predicted FEV1Standard Deviation 18.65
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-4.0 Percent predicted FEV1Standard Deviation 19.64
Total Ambulatory ParticipantsChange From Baseline in %pFEV1 at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-2.1 Percent predicted FEV1Standard Deviation 18.78
Primary

Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years

FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years-3.9 Percent predicted FEV1Standard Deviation 19.38
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years-10.2 Percent predicted FEV1Standard Deviation 20.94
Total Ambulatory ParticipantsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years-4.8 Percent predicted FEV1Standard Deviation 19.67
Primary

Change From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)

FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-3.9 Percent predicted FEV1Standard Deviation 19.38
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-10.2 Percent predicted FEV1Standard Deviation 20.94
Total Ambulatory ParticipantsChange From Baseline in %pFEV1 at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-4.8 Percent predicted FEV1Standard Deviation 19.67
Primary

Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years

FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years115.2 Percent predicted FEV1Standard Deviation 1037.35
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years-5.8 Percent predicted FEV1Standard Deviation 8.83
Total Ambulatory ParticipantsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years109.1 Percent predicted FEV1Standard Deviation 1010.75
Primary

Change From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)

FEV1 is the volume of air forcefully exhaled in 1 second and was measured using spirometry. The %pFEV1 was calculated from FEV1 (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for Spirometry. The pulmonary function assessments were performed only in participants \>=6 years old as pre-specified in protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-4.6 Percent predicted FEV1Standard Deviation 18.97
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-5.8 Percent predicted FEV1Standard Deviation 8.83
Total Ambulatory ParticipantsChange From Baseline in %pFEV1 at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-4.6 Percent predicted FEV1Standard Deviation 18.56
Primary

Change From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)

FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-2.9 Percent predicted FVCStandard Deviation 15.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-5.7 Percent predicted FVCStandard Deviation 19.79
Total Ambulatory ParticipantsChange From Baseline in %pFVC at Month 12: Participants Aged >=6 Years (Unplanned Analysis)-3.4 Percent predicted FVCStandard Deviation 16.52
Primary

Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years

FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years-4.3 Percent predicted FVCStandard Deviation 15.97
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years-14.1 Percent predicted FVCStandard Deviation 20.68
Total Ambulatory ParticipantsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years-5.7 Percent predicted FVCStandard Deviation 17.02
Primary

Change From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)

FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-4.3 Percent predicted FVCStandard Deviation 15.97
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-14.1 Percent predicted FVCStandard Deviation 20.68
Total Ambulatory ParticipantsChange From Baseline in %pFVC at Month 24: Participants Aged >=6 Years (Unplanned Analysis)-5.7 Percent predicted FVCStandard Deviation 17.02
Primary

Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years

FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years105.4 Percent predicted FVCStandard Deviation 975.57
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years-3.2 Percent predicted FVCStandard Deviation 9.41
Total Ambulatory ParticipantsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years99.9 Percent predicted FVCStandard Deviation 950.53
Primary

Change From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)

FVC is the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The percent predicted FVC was calculated from FVC (measured in liter) according to age, height (estimated height as derived from the ulna length for non-ambulatory participants), ethnicity, and gender using multi-ethnic reference values for spirometry. The pulmonary function assessments were performed in participants aged \>=6 years as pre-specified in the protocol. Incorrect data were addressed by unplanned analysis.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-7.2 Percent predicted FVCStandard Deviation 16.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-3.2 Percent predicted FVCStandard Deviation 9.41
Total Ambulatory ParticipantsChange From Baseline in %pFVC at Month 30: Participants Aged >=6 Years (Unplanned Analysis)-7.0 Percent predicted FVCStandard Deviation 16.12
Primary

Change From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years-0.6 Units on a scaleStandard Deviation 2.16
Ambulatory Participants With Age >=6 YearsChange From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years-0.9 Units on a scaleStandard Deviation 2.37
Total Ambulatory ParticipantsChange From Baseline in PUL 2.0 Total Score at Month 12: Participants Aged >=10 Years-0.7 Units on a scaleStandard Deviation 2.22
Primary

Change From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years-1.7 Units on a scaleStandard Deviation 3.22
Ambulatory Participants With Age >=6 YearsChange From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years-4.3 Units on a scaleStandard Deviation 2.75
Total Ambulatory ParticipantsChange From Baseline in PUL 2.0 Total Score at Month 18: Participants Aged >=10 Years-2.1 Units on a scaleStandard Deviation 3.23
Primary

Change From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years-2.8 Units on a scaleStandard Deviation 3.92
Ambulatory Participants With Age >=6 YearsChange From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years-2.9 Units on a scaleStandard Deviation 3.23
Total Ambulatory ParticipantsChange From Baseline in PUL 2.0 Total Score at Month 24: Participants Aged >=10 Years-2.8 Units on a scaleStandard Deviation 3.65
Primary

Change From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function. PUL 2.0 total score was assessed in participants aged \>=10 years only as pre-specified in protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years-1.7 Units on a scaleStandard Deviation 3.37
Ambulatory Participants With Age >=6 YearsChange From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years-3.8 Units on a scaleStandard Deviation 1.71
Total Ambulatory ParticipantsChange From Baseline in PUL 2.0 Total Score at Month 30: Participants Aged >=10 Years-2.1 Units on a scaleStandard Deviation 3.21
Primary

Change From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6

Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Left Ankle Joint-0.5 Degrees of passive dorsiflexionStandard Deviation 9.12
Ambulatory Participants With Age <6 YearsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Right Ankle Joint-1.2 Degrees of passive dorsiflexionStandard Deviation 8.59
Ambulatory Participants With Age >=6 YearsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Left Ankle Joint0.8 Degrees of passive dorsiflexionStandard Deviation 10.94
Ambulatory Participants With Age >=6 YearsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Right Ankle Joint-0.4 Degrees of passive dorsiflexionStandard Deviation 10.69
Total Ambulatory ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Left Ankle Joint0.3 Degrees of passive dorsiflexionStandard Deviation 10.31
Total Ambulatory ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Right Ankle Joint-0.7 Degrees of passive dorsiflexionStandard Deviation 9.96
Non-ambulatory ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Right Ankle Joint-8.2 Degrees of passive dorsiflexionStandard Deviation 5.45
Non-ambulatory ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Left Ankle Joint-8.2 Degrees of passive dorsiflexionStandard Deviation 8.5
Total ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Left Ankle Joint0.2 Degrees of passive dorsiflexionStandard Deviation 10.33
Total ParticipantsChange From Baseline in Range of Motion (ROM) at Bilateral Ankles at Month 6Right Ankle Joint-0.8 Degrees of passive dorsiflexionStandard Deviation 9.94
Primary

Change From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only

The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.08
Ambulatory Participants With Age >=6 YearsChange From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.07
Total Ambulatory ParticipantsChange From Baseline in Rise From Floor Velocity at Month 12: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.08
Primary

Change From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only

The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.08
Ambulatory Participants With Age >=6 YearsChange From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.06
Total Ambulatory ParticipantsChange From Baseline in Rise From Floor Velocity at Month 18: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.08
Primary

Change From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only

The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.09
Ambulatory Participants With Age >=6 YearsChange From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only-0.1 Rise per secondStandard Deviation 0.07
Total Ambulatory ParticipantsChange From Baseline in Rise From Floor Velocity at Month 24: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.09
Primary

Change From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only

The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.1
Ambulatory Participants With Age >=6 YearsChange From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only-0.1 Rise per secondStandard Deviation 0.08
Total Ambulatory ParticipantsChange From Baseline in Rise From Floor Velocity at Month 30: Ambulatory Participants Aged >=3 Years Only-0.1 Rise per secondStandard Deviation 0.1
Primary

Change From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only

The rise from floor velocity was defined as the reciprocal of the time (in seconds) to rise from floor. The rise from floor test was performed only in ambulatory participants aged \>=3 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.07
Ambulatory Participants With Age >=6 YearsChange From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only-0.0 Rise per secondStandard Deviation 0.05
Total Ambulatory ParticipantsChange From Baseline in Rise From Floor Velocity at Month 6: Ambulatory Participants Aged >=3 Years Only0.0 Rise per secondStandard Deviation 0.06
Primary

Change From Baseline in ROM at Bilateral Ankles at Month 12

Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 12Left Ankle Joint-2.6 Degrees of passive dorsiflexionStandard Deviation 10.13
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 12Right Ankle Joint-3.1 Degrees of passive dorsiflexionStandard Deviation 9.19
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 12Right Ankle Joint-2.8 Degrees of passive dorsiflexionStandard Deviation 10.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 12Left Ankle Joint-2.0 Degrees of passive dorsiflexionStandard Deviation 11.06
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Right Ankle Joint-2.9 Degrees of passive dorsiflexionStandard Deviation 10.31
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Left Ankle Joint-2.2 Degrees of passive dorsiflexionStandard Deviation 10.74
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Left Ankle Joint-11.6 Degrees of passive dorsiflexionStandard Deviation 18.18
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Right Ankle Joint-7.9 Degrees of passive dorsiflexionStandard Deviation 19.74
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Right Ankle Joint-3.4 Degrees of passive dorsiflexionStandard Deviation 11.7
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 12Left Ankle Joint-3.2 Degrees of passive dorsiflexionStandard Deviation 12.05
Primary

Change From Baseline in ROM at Bilateral Ankles at Month 18

Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 18Left Ankle Joint-1.8 Degrees of passive dorsiflexionStandard Deviation 9.19
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 18Right Ankle Joint-2.2 Degrees of passive dorsiflexionStandard Deviation 8.91
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 18Left Ankle Joint-4.0 Degrees of passive dorsiflexionStandard Deviation 10.9
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 18Right Ankle Joint-4.5 Degrees of passive dorsiflexionStandard Deviation 11.5
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Left Ankle Joint-3.1 Degrees of passive dorsiflexionStandard Deviation 10.28
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Right Ankle Joint-3.6 Degrees of passive dorsiflexionStandard Deviation 10.58
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Right Ankle Joint-5.0 Degrees of passive dorsiflexionStandard Deviation 4.24
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Left Ankle Joint-8.8 Degrees of passive dorsiflexionStandard Deviation 12.47
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Left Ankle Joint-3.2 Degrees of passive dorsiflexionStandard Deviation 10.32
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 18Right Ankle Joint-3.6 Degrees of passive dorsiflexionStandard Deviation 10.48
Primary

Change From Baseline in ROM at Bilateral Ankles at Month 24

Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 24Left Ankle Joint-2.8 Degrees of passive dorsiflexionStandard Deviation 8.59
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 24Right Ankle Joint-3.6 Degrees of passive dorsiflexionStandard Deviation 8.78
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 24Left Ankle Joint-4.8 Degrees of passive dorsiflexionStandard Deviation 12.09
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 24Right Ankle Joint-6.0 Degrees of passive dorsiflexionStandard Deviation 12.88
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Left Ankle Joint-4.1 Degrees of passive dorsiflexionStandard Deviation 11
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Right Ankle Joint-5.1 Degrees of passive dorsiflexionStandard Deviation 11.62
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Right Ankle Joint-11.4 Degrees of passive dorsiflexionStandard Deviation 15.77
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Left Ankle Joint-8.5 Degrees of passive dorsiflexionStandard Deviation 15.79
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Left Ankle Joint-4.6 Degrees of passive dorsiflexionStandard Deviation 11.59
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 24Right Ankle Joint-5.8 Degrees of passive dorsiflexionStandard Deviation 12.2
Primary

Change From Baseline in ROM at Bilateral Ankles at Month 30

Range of motion was evaluated by using goniometry to record any occurrences of ankle contractures. The ROM at left and right ankles were measured in degrees of passive dorsiflexion.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 30Left Ankle Joint0.3 Degrees of passive dorsiflexionStandard Deviation 9.5
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 30Right Ankle Joint0.1 Degrees of passive dorsiflexionStandard Deviation 8.08
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 30Left Ankle Joint-4.9 Degrees of passive dorsiflexionStandard Deviation 12.23
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Ankles at Month 30Right Ankle Joint-6.5 Degrees of passive dorsiflexionStandard Deviation 13.04
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Left Ankle Joint-3.4 Degrees of passive dorsiflexionStandard Deviation 11.71
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Right Ankle Joint-4.6 Degrees of passive dorsiflexionStandard Deviation 12.18
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Right Ankle Joint-2.5 Degrees of passive dorsiflexionStandard Deviation 6.24
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Left Ankle Joint-4.8 Degrees of passive dorsiflexionStandard Deviation 14.08
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Left Ankle Joint-3.5 Degrees of passive dorsiflexionStandard Deviation 11.73
Total ParticipantsChange From Baseline in ROM at Bilateral Ankles at Month 30Right Ankle Joint-4.5 Degrees of passive dorsiflexionStandard Deviation 12.01
Primary

Change From Baseline in ROM at Bilateral Elbows at Month 12

Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 12Right Elbow Joint-2.7 Degrees of passive extensionStandard Deviation 9.86
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 12Left Elbow Joint-2.3 Degrees of passive extensionStandard Deviation 10.33
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 12Right Elbow Joint-0.3 Degrees of passive extensionStandard Deviation 7.85
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 12Left Elbow Joint-1.3 Degrees of passive extensionStandard Deviation 7.9
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Right Elbow Joint-1.1 Degrees of passive extensionStandard Deviation 8.63
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Left Elbow Joint-1.6 Degrees of passive extensionStandard Deviation 8.77
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Left Elbow Joint-3.3 Degrees of passive extensionStandard Deviation 11.52
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Right Elbow Joint-2.7 Degrees of passive extensionStandard Deviation 11.19
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Right Elbow Joint-1.3 Degrees of passive extensionStandard Deviation 8.93
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 12Left Elbow Joint-1.8 Degrees of passive extensionStandard Deviation 9.1
Primary

Change From Baseline in ROM at Bilateral Elbows at Month 18

Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. Number Analyzed signifies participants evaluable for the specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 18Right Elbow Joint-1.6 Degrees of passive extensionStandard Deviation 8.44
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 18Left Elbow Joint-1.1 Degrees of passive extensionStandard Deviation 8.43
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 18Right Elbow Joint-1.8 Degrees of passive extensionStandard Deviation 8.03
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 18Left Elbow Joint-2.6 Degrees of passive extensionStandard Deviation 6.41
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Right Elbow Joint-1.7 Degrees of passive extensionStandard Deviation 8.18
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Left Elbow Joint-2.0 Degrees of passive extensionStandard Deviation 7.3
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Left Elbow Joint-10.3 Degrees of passive extensionStandard Deviation 2.63
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Right Elbow Joint-7.0 Degrees of passive extensionStandard Deviation 12.99
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Right Elbow Joint-1.8 Degrees of passive extensionStandard Deviation 8.28
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 18Left Elbow Joint-2.1 Degrees of passive extensionStandard Deviation 7.33
Primary

Change From Baseline in ROM at Bilateral Elbows at Month 24

Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 24Right Elbow Joint0.1 Degrees of passive extensionStandard Deviation 6.68
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 24Left Elbow Joint0.7 Degrees of passive extensionStandard Deviation 6.79
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 24Right Elbow Joint-1.0 Degrees of passive extensionStandard Deviation 7.42
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 24Left Elbow Joint-1.5 Degrees of passive extensionStandard Deviation 6.99
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Right Elbow Joint-0.6 Degrees of passive extensionStandard Deviation 7.17
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Left Elbow Joint-0.7 Degrees of passive extensionStandard Deviation 6.98
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Left Elbow Joint-5.7 Degrees of passive extensionStandard Deviation 13.87
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Right Elbow Joint-5.1 Degrees of passive extensionStandard Deviation 13.22
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Right Elbow Joint-1.1 Degrees of passive extensionStandard Deviation 8.04
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 24Left Elbow Joint-1.2 Degrees of passive extensionStandard Deviation 8.02
Primary

Change From Baseline in ROM at Bilateral Elbows at Month 30

Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 30Right Elbow Joint1.0 Degrees of passive extensionStandard Deviation 5.47
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 30Left Elbow Joint1.0 Degrees of passive extensionStandard Deviation 6.69
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 30Right Elbow Joint-1.9 Degrees of passive extensionStandard Deviation 7.52
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 30Left Elbow Joint-2.2 Degrees of passive extensionStandard Deviation 7.23
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Right Elbow Joint-1.1 Degrees of passive extensionStandard Deviation 7.1
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Left Elbow Joint-1.3 Degrees of passive extensionStandard Deviation 7.19
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Left Elbow Joint-9.0 Degrees of passive extensionStandard Deviation 14.26
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Right Elbow Joint-5.0 Degrees of passive extensionStandard Deviation 17.74
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Right Elbow Joint-1.2 Degrees of passive extensionStandard Deviation 7.6
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 30Left Elbow Joint-1.5 Degrees of passive extensionStandard Deviation 7.58
Primary

Change From Baseline in ROM at Bilateral Elbows at Month 6

Range of motion was evaluated by using goniometry to record any occurrences of elbow contractures. The ROM at left and right elbows were measured in degrees of passive extension.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 6Right Elbow Joint1.0 Degrees of passive extensionStandard Deviation 7.13
Ambulatory Participants With Age <6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 6Left Elbow Joint0.8 Degrees of passive extensionStandard Deviation 7.13
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 6Right Elbow Joint1.0 Degrees of passive extensionStandard Deviation 6.82
Ambulatory Participants With Age >=6 YearsChange From Baseline in ROM at Bilateral Elbows at Month 6Left Elbow Joint0.7 Degrees of passive extensionStandard Deviation 6.17
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Right Elbow Joint1.0 Degrees of passive extensionStandard Deviation 6.92
Total Ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Left Elbow Joint0.8 Degrees of passive extensionStandard Deviation 6.53
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Left Elbow Joint-4.0 Degrees of passive extensionStandard Deviation 2.92
Non-ambulatory ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Right Elbow Joint-3.2 Degrees of passive extensionStandard Deviation 7.79
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Right Elbow Joint0.9 Degrees of passive extensionStandard Deviation 6.95
Total ParticipantsChange From Baseline in ROM at Bilateral Elbows at Month 6Left Elbow Joint0.7 Degrees of passive extensionStandard Deviation 6.51
Primary

Change From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Shoulder Abduction0.5 KilogramsStandard Deviation 0.76
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Shoulder Abduction0.6 KilogramsStandard Deviation 0.86
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.89
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Shoulder Abduction0.5 KilogramsStandard Deviation 1
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.88
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Shoulder Abduction0.5 KilogramsStandard Deviation 0.99
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Shoulder Abduction0.1 KilogramsStandard Deviation 0.97
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Shoulder Abduction0.1 KilogramsStandard Deviation 0.82
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.88
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 12: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 0.99
Primary

Change From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 18

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Shoulder Abduction0.5 KilogramsStandard Deviation 0.65
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Shoulder Abduction0.8 KilogramsStandard Deviation 0.98
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.98
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 1.05
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.94
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Shoulder Abduction0.5 KilogramsStandard Deviation 1.04
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Shoulder Abduction-0.8 KilogramsStandard Deviation 0.55
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Shoulder Abduction-1.0 KilogramsStandard Deviation 0.6
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsLeft Shoulder Abduction0.3 KilogramsStandard Deviation 0.96
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 18: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 1.05
Primary

Change From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Shoulder Abduction1.1 KilogramsStandard Deviation 1.04
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Shoulder Abduction1.2 KilogramsStandard Deviation 1.11
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Shoulder Abduction0.3 KilogramsStandard Deviation 1.13
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Shoulder Abduction0.6 KilogramsStandard Deviation 1.25
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 1.15
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Shoulder Abduction0.6 KilogramsStandard Deviation 1.24
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Shoulder Abduction-0.1 KilogramsStandard Deviation 1.04
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Shoulder Abduction0.0 KilogramsStandard Deviation 0.8
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 1.12
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 24: Participants Aged >=5 YearsRight Shoulder Abduction0.5 KilogramsStandard Deviation 1.24
Primary

Change From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Shoulder Abduction0.6 KilogramsStandard Deviation 1.28
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Shoulder Abduction0.8 KilogramsStandard Deviation 0.93
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Shoulder Abduction0.6 KilogramsStandard Deviation 1.25
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Shoulder Abduction0.8 KilogramsStandard Deviation 1.34
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Shoulder Abduction0.6 KilogramsStandard Deviation 1.25
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Shoulder Abduction0.8 KilogramsStandard Deviation 1.31
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Shoulder Abduction1.3 KilogramsStandard Deviation 1.77
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Shoulder Abduction0.8 KilogramsStandard Deviation 1
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsLeft Shoulder Abduction0.6 KilogramsStandard Deviation 1.23
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 30: Participants Aged >=5 YearsRight Shoulder Abduction0.8 KilogramsStandard Deviation 1.32
Primary

Change From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 Years

Muscle strength was recorded by handheld myometry. Left and right shoulder abduction were analyzed. The muscle strength test was only performed in participants \>=5 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 6

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 1.15
Ambulatory Participants With Age <6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Shoulder Abduction0.5 KilogramsStandard Deviation 0.95
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.87
Ambulatory Participants With Age >=6 YearsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 0.9
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.91
Total Ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 0.9
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Shoulder Abduction0.3 KilogramsStandard Deviation 0.1
Non-ambulatory ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Shoulder Abduction-0.1 KilogramsStandard Deviation 0.45
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsLeft Shoulder Abduction0.4 KilogramsStandard Deviation 0.9
Total ParticipantsChange From Baseline in Shoulder Abduction of Muscle Strength at Month 6: Participants Aged >=5 YearsRight Shoulder Abduction0.4 KilogramsStandard Deviation 0.89
Primary

Change From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 Years

WISC-IV is an individually administered intelligence test for children between the ages of 6 and 16. The WISC-IV Composites are: Verbal Comprehension, Perceptual Reasoning, Working Memory, and Processing Speed. Scores from the Composites constitute the WISC-IV Full Scale IQ score which ranges from 40 (Exceptionally Low) to 160 (Exceptionally Superior), higher scores indicated more intelligence. The WISC was only performed in ambulatory participants \>= 6 to \<=16 years old as pre-specified in the protocol.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Wechsler Intelligence Scale for Children (WISC)-IV Score at Month 24: Ambulatory Participants >= 6 to <=16 Years1.0 Units on a scaleStandard Deviation 8.59
Secondary

Change From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30

EQ-5D-3L index score, participants rated their current health state on 5 single-item dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with each dimension having three levels of severity: 1=no problems, 2=some problems and 3=extreme problems. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total index score range of 0 to 1.00. Higher scores indicating a better quality of life. EQ-5D-3L was only performed in participants \>= 16 years old.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \>=16 years. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 12-0.0 Units on a scaleStandard Deviation 0.14
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 24-0.2 Units on a scaleStandard Deviation 0.16
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 30-0.3 Units on a scale
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 12-0.0 Units on a scaleStandard Deviation 0.14
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 24-0.2 Units on a scaleStandard Deviation 0.16
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Index Score at Months 12, 24 and 30Month 30-0.3 Units on a scale
Secondary

Change From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30

EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state), where higher scores indicated better quality of life. EQ-VAS assessment was only performed in the participants \>= 16 years old.

Time frame: Baseline (Day 1) and Months 12, 24 and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \>=16 years. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 12-4.0 Units on a scaleStandard Deviation 9.54
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 24-11.3 Units on a scaleStandard Deviation 7.37
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 30-14.0 Units on a scale
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 12-4.0 Units on a scaleStandard Deviation 9.54
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 24-11.3 Units on a scaleStandard Deviation 7.37
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-3L Visual Analogue Score (VAS) Assessment at Months 12, 24 and 30Month 30-14.0 Units on a scale
Secondary

Change From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30

EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<=16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems. Participants indicated their health state by choosing the appropriate level from each dimension. The 5 digit health states thus obtained for each dimension were then converted into a single median index value. A health state index score was calculated from individual health profiles using a USA scoring algorithm. Health state index scores generally ranged from -0.109 to 1, where, -0.109= the worst health status, 1= full health. Higher the score the better the better quality of life.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \<16 years and contributed data to table, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 12-0.0 Units on a scaleStandard Deviation 0.12
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 300.0 Units on a scaleStandard Deviation 0.09
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 240.0 Units on a scaleStandard Deviation 0.13
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 24-0.1 Units on a scaleStandard Deviation 0.16
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 12-0.0 Units on a scaleStandard Deviation 0.16
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 30-0.1 Units on a scaleStandard Deviation 0.18
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 24-0.1 Units on a scaleStandard Deviation 0.16
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 12-0.0 Units on a scaleStandard Deviation 0.15
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 30-0.1 Units on a scaleStandard Deviation 0.17
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 12-0.0 Units on a scaleStandard Deviation 0.13
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 300.0 Units on a scaleStandard Deviation 0.09
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 24-0.0 Units on a scaleStandard Deviation 0.12
Total ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 24-0.1 Units on a scaleStandard Deviation 0.16
Total ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 12-0.0 Units on a scaleStandard Deviation 0.15
Total ParticipantsChange From Baseline in EQ-5D-Y Index Score at Months 12, 24, and 30Month 30-0.1 Units on a scaleStandard Deviation 0.17
Secondary

Change From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30

EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. EQ-VAS recorded the participant's self-rated health on a vertical scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with age \<16 years and contributed data to table, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 30-1.0 Units on a scaleStandard Deviation 12.16
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 24-3.0 Units on a scaleStandard Deviation 15.08
Ambulatory Participants With Age <6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 12-1.0 Units on a scaleStandard Deviation 19.84
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 30-6.1 Units on a scaleStandard Deviation 21.71
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 12-4.3 Units on a scaleStandard Deviation 23.02
Ambulatory Participants With Age >=6 YearsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 24-5.6 Units on a scaleStandard Deviation 21.59
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 30-5.1 Units on a scaleStandard Deviation 20.3
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 24-5.0 Units on a scaleStandard Deviation 20.19
Total Ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 12-3.5 Units on a scaleStandard Deviation 22.36
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 305.0 Units on a scaleStandard Deviation 5
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 12-5.0 Units on a scaleStandard Deviation 22.94
Non-ambulatory ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 24-5.9 Units on a scaleStandard Deviation 14.59
Total ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 12-3.7 Units on a scaleStandard Deviation 22.37
Total ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 30-4.8 Units on a scaleStandard Deviation 20.07
Total ParticipantsChange From Baseline in EQ-5D-Y VAS Assessment at Months 12, 24, and 30Month 24-5.1 Units on a scaleStandard Deviation 19.78
Secondary

Change From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30

HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to their child's use of healthcare professionals, emergency room visits, and hospitalizations in past 3 months. Change from baseline in mean number of visits to primary care physician, emergency room and office visits is presented in this outcome measure.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Number of Participants Analyzed' signifies all participants in the Full Analysis Set. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 24-0.0 VisitsStandard Deviation 0.12
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 24-0.4 VisitsStandard Deviation 9.09
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 12-0.1 VisitsStandard Deviation 0.27
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 12-0.1 VisitsStandard Deviation 0.45
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 30-0.1 VisitsStandard Deviation 0.4
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 30-2.0 VisitsStandard Deviation 12.84
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 12-1.6 VisitsStandard Deviation 7.04
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 30-0.1 VisitsStandard Deviation 0.43
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 240.0 VisitsStandard Deviation 0.57
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 12-0.0 VisitsStandard Deviation 0.11
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 240.0 VisitsStandard Deviation 0.23
Ambulatory Participants With Age <6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 30-0.0 VisitsStandard Deviation 0.18
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 30-0.2 VisitsStandard Deviation 7.6
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 30-0.1 VisitsStandard Deviation 0.44
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 24-0.0 VisitsStandard Deviation 0.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 120.0 VisitsStandard Deviation 0.27
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 12-0.0 VisitsStandard Deviation 0.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 240.5 VisitsStandard Deviation 6.44
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 300.0 VisitsStandard Deviation 0.55
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 240.0 VisitsStandard Deviation 0.1
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 120.5 VisitsStandard Deviation 5.58
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 12-0.0 VisitsStandard Deviation 0.4
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 30-0.0 VisitsStandard Deviation 0.2
Ambulatory Participants With Age >=6 YearsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 24-0.1 VisitsStandard Deviation 0.36
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 240.2 VisitsStandard Deviation 7.48
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 12-0.0 VisitsStandard Deviation 0.37
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 24-0.0 VisitsStandard Deviation 0.35
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 30-0.0 VisitsStandard Deviation 0.53
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 12-0.1 VisitsStandard Deviation 0.42
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 24-0.0 VisitsStandard Deviation 0.44
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 30-0.1 VisitsStandard Deviation 0.43
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 12-0.0 VisitsStandard Deviation 0.23
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 240.0 VisitsStandard Deviation 0.1
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 30-0.0 VisitsStandard Deviation 0.19
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 12-0.2 VisitsStandard Deviation 6.18
Total Ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 30-0.7 VisitsStandard Deviation 9.32
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 300.0 VisitsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 12-0.0 VisitsStandard Deviation 0.18
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 240.0 VisitsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 24-0.2 VisitsStandard Deviation 0.52
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 300.0 VisitsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 12-0.1 VisitsStandard Deviation 0.35
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 30-17.0 VisitsStandard Deviation 32.67
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 12-3.4 VisitsStandard Deviation 11.2
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 300.0 VisitsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 240.1 VisitsStandard Deviation 0.51
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 24-6.2 VisitsStandard Deviation 15.7
Non-ambulatory ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 120.0 VisitsStandard Deviation 0
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 30-0.1 VisitsStandard Deviation 0.42
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 12-0.6 VisitsStandard Deviation 6.96
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 12-0.0 VisitsStandard Deviation 0.36
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 240.0 VisitsStandard Deviation 0.09
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 24-0.0 VisitsStandard Deviation 0.37
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 12-0.1 VisitsStandard Deviation 0.41
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 30-1.3 VisitsStandard Deviation 11.04
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To General Practitioner at Month 24-0.1 VisitsStandard Deviation 0.45
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 30-0.0 VisitsStandard Deviation 0.19
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To ER Due to Disease at Month 12-0.0 VisitsStandard Deviation 0.22
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30To Primary Care Physician at Month 30-0.0 VisitsStandard Deviation 0.52
Total ParticipantsChange From Baseline in Healthcare Resource Utilization (HRU) Survey Responses: Visit to Primary Care Physician, Emergency Room and Office Visits at Months 12, 24, and 30Office Visits at Month 24-0.5 VisitsStandard Deviation 8.78
Secondary

Change From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30

HRU questionnaire is completed by the caregiver and had questions about healthcare resources utilization related to number of nights in hospital due to disease/dedication for disease in past 3 months. Change from baseline in mean number of nights in hospital due to disease or medication for disease is presented in this outcome measure.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 12-0.2 NightsStandard Deviation 1.02
Ambulatory Participants With Age <6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 300.0 NightsStandard Deviation 0
Ambulatory Participants With Age <6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 24-0.2 NightsStandard Deviation 1.06
Ambulatory Participants With Age >=6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 24-0.2 NightsStandard Deviation 1.97
Ambulatory Participants With Age >=6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 12-0.2 NightsStandard Deviation 1.82
Ambulatory Participants With Age >=6 YearsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 30-0.1 NightsStandard Deviation 0.79
Total Ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 24-0.2 NightsStandard Deviation 1.7
Total Ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 12-0.2 NightsStandard Deviation 1.6
Total Ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 30-0.1 NightsStandard Deviation 0.67
Non-ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 120.0 NightsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 300.0 NightsStandard Deviation 0
Non-ambulatory ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 240.2 NightsStandard Deviation 0.83
Total ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 24-0.2 NightsStandard Deviation 1.64
Total ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 12-0.2 NightsStandard Deviation 1.51
Total ParticipantsChange From Baseline in HRU Survey Responses: Number of Nights in Hospital Due to Disease/Medication for Disease at Months 12, 24, and 30Month 30-0.1 NightsStandard Deviation 0.66
Secondary

Change From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30

Caregivers were asked to estimate out-of-pocket costs related to healthcare resource utilization. The number of out of pocket money was defined as the total spent of the past three months in managing child's Duchenne muscular dystrophy.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 30-1794.5 Chinese Yuan (CYN)Standard Deviation 6772.8
Ambulatory Participants With Age <6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 24352.8 Chinese Yuan (CYN)Standard Deviation 8484.07
Ambulatory Participants With Age <6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 12-2748.1 Chinese Yuan (CYN)Standard Deviation 6100.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 24777.6 Chinese Yuan (CYN)Standard Deviation 7630.02
Ambulatory Participants With Age >=6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 12476.0 Chinese Yuan (CYN)Standard Deviation 10947.21
Ambulatory Participants With Age >=6 YearsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 301213.6 Chinese Yuan (CYN)Standard Deviation 6820.65
Total Ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 30378.0 Chinese Yuan (CYN)Standard Deviation 6909.59
Total Ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 12-598.7 Chinese Yuan (CYN)Standard Deviation 9713.33
Total Ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 24627.3 Chinese Yuan (CYN)Standard Deviation 7925.23
Non-ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 30-675.0 Chinese Yuan (CYN)Standard Deviation 4592.29
Non-ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 121836.7 Chinese Yuan (CYN)Standard Deviation 6410.95
Non-ambulatory ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 242326.1 Chinese Yuan (CYN)Standard Deviation 6126.93
Total ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 12-328.1 Chinese Yuan (CYN)Standard Deviation 9425.78
Total ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 24793.6 Chinese Yuan (CYN)Standard Deviation 7773.09
Total ParticipantsChange From Baseline in Out-of-Pocket Money of HRU Survey at Months 12, 24 and 30Month 30340.4 Chinese Yuan (CYN)Standard Deviation 6828.66
Secondary

Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30

The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.

Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age \<=10 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 301.1 Units on a scaleStandard Deviation 10.29
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-1.1 Units on a scaleStandard Deviation 14.61
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 181.6 Units on a scaleStandard Deviation 8.38
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 61.0 Units on a scaleStandard Deviation 7.99
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 182.6 Units on a scaleStandard Deviation 14.05
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 122.7 Units on a scaleStandard Deviation 14.76
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-0.5 Units on a scaleStandard Deviation 8.69
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 304.9 Units on a scaleStandard Deviation 12.73
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 61.6 Units on a scaleStandard Deviation 13.79
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 301.0 Units on a scaleStandard Deviation 6.23
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 182.0 Units on a scaleStandard Deviation 10.54
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-2.3 Units on a scaleStandard Deviation 10.32
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-4.4 Units on a scaleStandard Deviation 19.15
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 61.2 Units on a scaleStandard Deviation 9.58
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-0.8 Units on a scaleStandard Deviation 11.41
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 181.1 Units on a scaleStandard Deviation 9.54
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 184.2 Units on a scaleStandard Deviation 14.59
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 122.4 Units on a scaleStandard Deviation 14.41
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 304.1 Units on a scaleStandard Deviation 9.9
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 120.7 Units on a scaleStandard Deviation 10.9
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 60.2 Units on a scaleStandard Deviation 15.69
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-6.4 Units on a scaleStandard Deviation 13.8
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 61.5 Units on a scaleStandard Deviation 7.91
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-0.1 Units on a scaleStandard Deviation 5.81
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-7.1 Units on a scaleStandard Deviation 18.46
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-2.1 Units on a scaleStandard Deviation 19.31
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-1.4 Units on a scaleStandard Deviation 16.72
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 121.9 Units on a scaleStandard Deviation 7.67
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 121.0 Units on a scaleStandard Deviation 9.04
Ambulatory Participants With Age <6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-0.3 Units on a scaleStandard Deviation 16.88
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-4.2 Units on a scaleStandard Deviation 22.57
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 60.3 Units on a scaleStandard Deviation 7.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-1.4 Units on a scaleStandard Deviation 11.05
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 18-0.3 Units on a scaleStandard Deviation 9.13
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-4.1 Units on a scaleStandard Deviation 11.83
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-2.2 Units on a scaleStandard Deviation 10.91
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-1.2 Units on a scaleStandard Deviation 8.59
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-5.5 Units on a scaleStandard Deviation 14.75
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-4.1 Units on a scaleStandard Deviation 12.12
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-9.8 Units on a scaleStandard Deviation 15.48
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-11.0 Units on a scaleStandard Deviation 17.83
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-1.5 Units on a scaleStandard Deviation 12.75
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-7.5 Units on a scaleStandard Deviation 15.78
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-7.5 Units on a scaleStandard Deviation 15.88
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-12.4 Units on a scaleStandard Deviation 16.74
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-19.9 Units on a scaleStandard Deviation 20.49
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 61.0 Units on a scaleStandard Deviation 19.01
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-5.0 Units on a scaleStandard Deviation 21.95
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-3.7 Units on a scaleStandard Deviation 20.12
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-8.5 Units on a scaleStandard Deviation 21.36
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-15.2 Units on a scaleStandard Deviation 19.27
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 60.0 Units on a scaleStandard Deviation 20.09
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-5.6 Units on a scaleStandard Deviation 23.49
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-12.3 Units on a scaleStandard Deviation 21.44
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-12.8 Units on a scaleStandard Deviation 20.68
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-0.4 Units on a scaleStandard Deviation 8.65
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-4.9 Units on a scaleStandard Deviation 12.12
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-3.9 Units on a scaleStandard Deviation 10.05
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-8.7 Units on a scaleStandard Deviation 10.99
Ambulatory Participants With Age >=6 YearsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-12.0 Units on a scaleStandard Deviation 13.73
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-7.0 Units on a scaleStandard Deviation 16.69
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-2.6 Units on a scaleStandard Deviation 11.36
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-10.5 Units on a scaleStandard Deviation 19.64
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-2.6 Units on a scaleStandard Deviation 12.95
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 60.5 Units on a scaleStandard Deviation 18.13
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-3.6 Units on a scaleStandard Deviation 20.09
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-2.9 Units on a scaleStandard Deviation 19.69
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-0.1 Units on a scaleStandard Deviation 8.4
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-7.8 Units on a scaleStandard Deviation 19.97
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-1.6 Units on a scaleStandard Deviation 10.1
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-11.2 Units on a scaleStandard Deviation 17.45
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 300.6 Units on a scaleStandard Deviation 10.85
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 60.1 Units on a scaleStandard Deviation 18.37
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-2.4 Units on a scaleStandard Deviation 20.74
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-2.5 Units on a scaleStandard Deviation 11.71
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-0.3 Units on a scaleStandard Deviation 19.65
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 180.8 Units on a scaleStandard Deviation 9.85
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-6.7 Units on a scaleStandard Deviation 12.37
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-8.5 Units on a scaleStandard Deviation 20.69
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-5.7 Units on a scaleStandard Deviation 11.11
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-4.9 Units on a scaleStandard Deviation 19.54
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 60.2 Units on a scaleStandard Deviation 8.39
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-5.6 Units on a scaleStandard Deviation 15.02
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-5.4 Units on a scaleStandard Deviation 13.47
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-0.2 Units on a scaleStandard Deviation 13.24
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-3.5 Units on a scaleStandard Deviation 16.14
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-1.4 Units on a scaleStandard Deviation 10.89
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-0.6 Units on a scaleStandard Deviation 11.01
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-2.8 Units on a scaleStandard Deviation 15.83
Total Ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 60.7 Units on a scaleStandard Deviation 8.47
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-4.3 Units on a scaleStandard Deviation 3.1
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-10.0 Units on a scaleStandard Deviation 7.07
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 616.5 Units on a scaleStandard Deviation 12.02
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-17.5 Units on a scaleStandard Deviation 11.9
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 67.5 Units on a scaleStandard Deviation 10.61
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-2.8 Units on a scaleStandard Deviation 17.02
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 61.0 Units on a scaleStandard Deviation 7.07
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-5.5 Units on a scaleStandard Deviation 6.4
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 65.5 Units on a scaleStandard Deviation 7.78
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-6.8 Units on a scaleStandard Deviation 14.2
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 67.5 Units on a scaleStandard Deviation 14.85
Non-ambulatory ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-8.3 Units on a scaleStandard Deviation 17.56
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-2.6 Units on a scaleStandard Deviation 12.99
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-7.0 Units on a scaleStandard Deviation 16.69
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-7.8 Units on a scaleStandard Deviation 19.97
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 300.6 Units on a scaleStandard Deviation 10.85
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-0.2 Units on a scaleStandard Deviation 13.19
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-10.5 Units on a scaleStandard Deviation 19.64
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-8.5 Units on a scaleStandard Deviation 20.69
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-5.7 Units on a scaleStandard Deviation 11.11
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-0.7 Units on a scaleStandard Deviation 11.17
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-5.4 Units on a scaleStandard Deviation 13.47
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 60.5 Units on a scaleStandard Deviation 18.06
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 60.0 Units on a scaleStandard Deviation 8.46
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-2.7 Units on a scaleStandard Deviation 11.28
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-1.4 Units on a scaleStandard Deviation 10.89
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-11.2 Units on a scaleStandard Deviation 17.45
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-3.7 Units on a scaleStandard Deviation 19.96
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-2.8 Units on a scaleStandard Deviation 15.83
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 60.8 Units on a scaleStandard Deviation 8.61
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 60.3 Units on a scaleStandard Deviation 8.41
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-2.9 Units on a scaleStandard Deviation 19.69
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-0.0 Units on a scaleStandard Deviation 18.32
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-2.5 Units on a scaleStandard Deviation 11.71
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-4.9 Units on a scaleStandard Deviation 19.54
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-5.6 Units on a scaleStandard Deviation 15.02
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-6.7 Units on a scaleStandard Deviation 12.37
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-2.7 Units on a scaleStandard Deviation 20.69
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-3.5 Units on a scaleStandard Deviation 15.98
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 180.8 Units on a scaleStandard Deviation 9.85
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-1.6 Units on a scaleStandard Deviation 10.1
Total ParticipantsChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Global Functioning Scale and Each Core Scale Score (Pediatric Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-0.3 Units on a scaleStandard Deviation 19.65
Secondary

Change From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 12-6.6 Percentage activity impairmentStandard Deviation 30.71
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 30-6.7 Percentage activity impairmentStandard Deviation 31.14
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 247.4 Percentage activity impairmentStandard Deviation 32.22
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 248.8 Percentage activity impairmentStandard Deviation 34.68
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 125.6 Percentage activity impairmentStandard Deviation 32.08
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 3013.8 Percentage activity impairmentStandard Deviation 30.82
Total Ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 248.3 Percentage activity impairmentStandard Deviation 33.76
Total Ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 122.0 Percentage activity impairmentStandard Deviation 32.09
Total Ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 3010.1 Percentage activity impairmentStandard Deviation 31.65
Non-ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 12-6.8 Percentage activity impairmentStandard Deviation 34.37
Non-ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 300.0 Percentage activity impairment
Non-ambulatory ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 24-7.9 Percentage activity impairmentStandard Deviation 31.02
Total ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 246.6 Percentage activity impairmentStandard Deviation 33.77
Total ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 120.9 Percentage activity impairmentStandard Deviation 32.41
Total ParticipantsChange From Baseline in Percent Activity Impairment as Per Work Productivity and Activity Impairment Questionnaire Adapted for Caregiving (WPAI:CG) Caregiver Unchanged at Months 12, 24, and 30Month 3010.0 Percentage activity impairmentStandard Deviation 31.43
Secondary

Change From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Baseline (Day 1) and Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 12-5.2 Percentage work impairmentStandard Deviation 26.25
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 240.2 Percentage work impairmentStandard Deviation 27.83
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 30-11.9 Percentage work impairmentStandard Deviation 35.09
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 12-3.7 Percentage work impairmentStandard Deviation 19.87
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 24-1.2 Percentage work impairmentStandard Deviation 25.47
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 301.1 Percentage work impairmentStandard Deviation 28.48
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 243.1 Percentage work impairmentStandard Deviation 26.82
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 305.3 Percentage work impairmentStandard Deviation 25.03
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 122.6 Percentage work impairmentStandard Deviation 25.35
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 306.8 Percentage work impairmentStandard Deviation 24.29
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 124.7 Percentage work impairmentStandard Deviation 24.08
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 244.8 Percentage work impairmentStandard Deviation 26.78
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 121.5 Percentage work impairmentStandard Deviation 22.84
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 241.2 Percentage work impairmentStandard Deviation 26.15
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 12-0.4 Percentage work impairmentStandard Deviation 25.83
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 300.8 Percentage work impairmentStandard Deviation 28.94
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 242.7 Percentage work impairmentStandard Deviation 27.16
Total Ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 303.9 Percentage work impairmentStandard Deviation 25.72
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 12-14.0 Percentage work impairmentStandard Deviation 33.4
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 24-12.7 Percentage work impairmentStandard Deviation 39.72
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 3030.0 Percentage work impairment
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 3030.0 Percentage work impairment
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 24-15.0 Percentage work impairmentStandard Deviation 37.49
Non-ambulatory ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 12-9.3 Percentage work impairmentStandard Deviation 36.17
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 24-0.7 Percentage work impairmentStandard Deviation 27.94
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 301.8 Percentage work impairmentStandard Deviation 28.93
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 240.9 Percentage work impairmentStandard Deviation 29.09
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 304.8 Percentage work impairmentStandard Deviation 25.72
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent impairment while working, Month 120.0 Percentage work impairmentStandard Deviation 24.29
Total ParticipantsChange From Baseline in Percent Overall Work Impairment WPAI: CG Caregiver Unchanged at Months 12, 24, and 30Percent Overall Work Impairment, Month 12-1.3 Percentage work impairmentStandard Deviation 26.93
Secondary

Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Baseline (Day 1) and Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12-6.1 Percentage work time missedStandard Deviation 25.47
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12-5.0 Percentage work time missedStandard Deviation 25.17
Total Ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12-5.5 Percentage work time missedStandard Deviation 25.15
Non-ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 123.7 Percentage work time missedStandard Deviation 18.59
Total ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 12-4.5 Percentage work time missedStandard Deviation 24.63
Secondary

Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Baseline (Day 1) and Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 241.1 Percentage work time missedStandard Deviation 24.46
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 240.9 Percentage work time missedStandard Deviation 29.04
Total Ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 241.0 Percentage work time missedStandard Deviation 26.91
Non-ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 24-4.4 Percentage work time missedStandard Deviation 23.92
Total ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 240.3 Percentage work time missedStandard Deviation 26.47
Secondary

Change From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Baseline (Day 1) and Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30-21.5 Percentage work time missedStandard Deviation 26.9
Ambulatory Participants With Age >=6 YearsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 302.0 Percentage work time missedStandard Deviation 14.15
Total Ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30-5.6 Percentage work time missedStandard Deviation 21.73
Non-ambulatory ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 300.0 Percentage work time missed
Total ParticipantsChange From Baseline in Percent Work Time Missed as Per WPAI: CG Caregiver Unchanged at Month 30-5.4 Percentage work time missedStandard Deviation 21.36
Secondary

Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30

The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.

Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age between 11-18 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-5.9 Units on a scaleStandard Deviation 14.24
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-10.0 Units on a scaleStandard Deviation 9.34
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-13.1 Units on a scaleStandard Deviation 19.57
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-12.4 Units on a scaleStandard Deviation 15.44
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-7.4 Units on a scaleStandard Deviation 10.21
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-25.9 Units on a scaleStandard Deviation 22.04
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-18.8 Units on a scaleStandard Deviation 17.62
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-2.1 Units on a scaleStandard Deviation 8.82
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-14.2 Units on a scaleStandard Deviation 20.41
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-23.8 Units on a scaleStandard Deviation 17.52
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-5.0 Units on a scaleStandard Deviation 8.34
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-4.1 Units on a scaleStandard Deviation 20.3
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-24.7 Units on a scaleStandard Deviation 17.74
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-5.1 Units on a scaleStandard Deviation 13.87
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-9.0 Units on a scaleStandard Deviation 20.31
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-7.2 Units on a scaleStandard Deviation 14.64
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-19.0 Units on a scaleStandard Deviation 12.31
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-17.9 Units on a scaleStandard Deviation 24.3
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-14.6 Units on a scaleStandard Deviation 17.24
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 18-6.4 Units on a scaleStandard Deviation 8.34
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-22.3 Units on a scaleStandard Deviation 20.23
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-19.3 Units on a scaleStandard Deviation 15.26
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-21.7 Units on a scaleStandard Deviation 16.19
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-11.0 Units on a scaleStandard Deviation 13.47
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-27.1 Units on a scaleStandard Deviation 21.79
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-12.1 Units on a scaleStandard Deviation 8.56
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-15.3 Units on a scaleStandard Deviation 16.31
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-28.4 Units on a scaleStandard Deviation 25.83
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-4.4 Units on a scaleStandard Deviation 9.24
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-17.4 Units on a scaleStandard Deviation 19.43
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-10.0 Units on a scaleStandard Deviation 22.91
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-18.8 Units on a scaleStandard Deviation 8.42
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-2.4 Units on a scaleStandard Deviation 16.17
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 181.3 Units on a scaleStandard Deviation 9.24
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-7.5 Units on a scaleStandard Deviation 16.51
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-8.0 Units on a scaleStandard Deviation 11.31
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-5.8 Units on a scaleStandard Deviation 5.62
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-9.2 Units on a scaleStandard Deviation 13.31
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 185.7 Units on a scaleStandard Deviation 20.65
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-10.3 Units on a scaleStandard Deviation 12.68
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-1.5 Units on a scaleStandard Deviation 6.36
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-3.0 Units on a scaleStandard Deviation 7.87
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-5.4 Units on a scaleStandard Deviation 11.21
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-4.7 Units on a scaleStandard Deviation 4.73
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-2.6 Units on a scaleStandard Deviation 8.99
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-9.5 Units on a scaleStandard Deviation 13.44
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-0.5 Units on a scaleStandard Deviation 22.65
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 1211.3 Units on a scaleStandard Deviation 34.97
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-10.3 Units on a scaleStandard Deviation 12.01
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 244.9 Units on a scaleStandard Deviation 29.67
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 309.0 Units on a scaleStandard Deviation 12.73
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 67.5 Units on a scaleStandard Deviation 36.63
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 121.6 Units on a scaleStandard Deviation 22.24
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-2.1 Units on a scaleStandard Deviation 25.74
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-17.5 Units on a scaleStandard Deviation 24.75
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-7.3 Units on a scaleStandard Deviation 7.76
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-1.5 Units on a scaleStandard Deviation 12.1
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-2.0 Units on a scaleStandard Deviation 3.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-3.8 Units on a scaleStandard Deviation 12.63
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-2.5 Units on a scaleStandard Deviation 2.12
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-5.5 Units on a scaleStandard Deviation 13.52
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 18-5.1 Units on a scaleStandard Deviation 8.72
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-10.5 Units on a scaleStandard Deviation 22.71
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-22.4 Units on a scaleStandard Deviation 25.42
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-4.3 Units on a scaleStandard Deviation 10.32
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-9.2 Units on a scaleStandard Deviation 22.54
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-19.4 Units on a scaleStandard Deviation 19.84
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-15.2 Units on a scaleStandard Deviation 18.27
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-14.4 Units on a scaleStandard Deviation 16.88
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-12.2 Units on a scaleStandard Deviation 15.73
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-10.4 Units on a scaleStandard Deviation 8.77
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-13.0 Units on a scaleStandard Deviation 24.79
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-5.2 Units on a scaleStandard Deviation 13.03
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-3.5 Units on a scaleStandard Deviation 12.57
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-17.8 Units on a scaleStandard Deviation 22.79
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-7.6 Units on a scaleStandard Deviation 9.71
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-17.4 Units on a scaleStandard Deviation 16.4
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-6.3 Units on a scaleStandard Deviation 15.57
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-21.3 Units on a scaleStandard Deviation 17.42
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-5.3 Units on a scaleStandard Deviation 8.18
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 12-0.3 Units on a scaleStandard Deviation 29.07
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-14.1 Units on a scaleStandard Deviation 17.69
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-9.4 Units on a scaleStandard Deviation 14.83
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-5.2 Units on a scaleStandard Deviation 19.03
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-16.4 Units on a scaleStandard Deviation 16.96
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-12.0 Units on a scaleStandard Deviation 14.48
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-5.4 Units on a scaleStandard Deviation 26.52
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-9.4 Units on a scaleStandard Deviation 14.07
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-6.4 Units on a scaleStandard Deviation 11.32
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Parent Report) at Months 6, 12, 18, 24 and 30Pain, Month 30-18.1 Units on a scaleStandard Deviation 24.92
Secondary

Change From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30

The PODCI is a participant-reported assessment of musculoskeletal health intended for use in children and adolescents. The pediatric version was intended for completion by parents or caregivers of children \<=10 years old. It included a Global Function Scale along with core scales: Upper Extremity and Physical Function Core Scale (8 items); Transfer and Basic Mobility Core Scale (11 items); Sports and Physical Functioning Core Scale (21 items); Pain/Comfort Core Scale (3 items); Happiness Core Scale (5 items). The scores of each PODCI global functioning scale and core scales are averaged over the number of items answered (omitted no entry items). Mean of the rescaled values is multiplied by a constant so that each global functioning scale and core scales has a final range of values between 0-100. The higher scores represent less disability and better functioning.

Time frame: Baseline (Day 1) and Months 6, 12, 18, 24 and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies all participants in the Full Analysis Set with age between 11-18 years contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-0.9 Units on a scaleStandard Deviation 14.11
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-5.3 Units on a scaleStandard Deviation 10.93
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 3013.9 Units on a scaleStandard Deviation 23.1
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-4.6 Units on a scaleStandard Deviation 19.6
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-4.4 Units on a scaleStandard Deviation 12.66
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-12.4 Units on a scaleStandard Deviation 24.21
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-8.7 Units on a scaleStandard Deviation 14.39
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-5.4 Units on a scaleStandard Deviation 7.16
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-2.6 Units on a scaleStandard Deviation 17.19
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-21.4 Units on a scaleStandard Deviation 19.71
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-4.6 Units on a scaleStandard Deviation 10.1
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 122.1 Units on a scaleStandard Deviation 26.07
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-10.4 Units on a scaleStandard Deviation 13.45
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-2.4 Units on a scaleStandard Deviation 6.62
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-2.7 Units on a scaleStandard Deviation 17.96
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-4.5 Units on a scaleStandard Deviation 10.71
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-1.6 Units on a scaleStandard Deviation 8.15
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-2.9 Units on a scaleStandard Deviation 16.29
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-10.6 Units on a scaleStandard Deviation 18.2
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-15.9 Units on a scaleStandard Deviation 12.85
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-2.0 Units on a scaleStandard Deviation 31.47
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-9.6 Units on a scaleStandard Deviation 11.78
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 180.3 Units on a scaleStandard Deviation 7.14
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-3.3 Units on a scaleStandard Deviation 17.29
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-24.9 Units on a scaleStandard Deviation 19.56
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-4.7 Units on a scaleStandard Deviation 12.46
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-4.8 Units on a scaleStandard Deviation 23.34
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-17.0 Units on a scaleStandard Deviation 19.71
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-5.0 Units on a scaleStandard Deviation 7.52
Ambulatory Participants With Age <6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-7.8 Units on a scaleStandard Deviation 23.14
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-8.3 Units on a scaleStandard Deviation 7.64
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-1.0 Units on a scaleStandard Deviation 8.29
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-3.3 Units on a scaleStandard Deviation 13.53
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 18-5.7 Units on a scaleStandard Deviation 12.7
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-2.0 Units on a scaleStandard Deviation 2.83
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-2.0 Units on a scaleStandard Deviation 18.09
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-6.3 Units on a scaleStandard Deviation 16.4
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-9.7 Units on a scaleStandard Deviation 4.04
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-7.9 Units on a scaleStandard Deviation 16.34
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-10.0 Units on a scaleStandard Deviation 8.49
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-2.8 Units on a scaleStandard Deviation 10.4
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-3.2 Units on a scaleStandard Deviation 11.03
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-2.7 Units on a scaleStandard Deviation 7.77
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-8.2 Units on a scaleStandard Deviation 12.58
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-1.5 Units on a scaleStandard Deviation 2.12
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 65.5 Units on a scaleStandard Deviation 11.47
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 128.3 Units on a scaleStandard Deviation 20.53
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-7.7 Units on a scaleStandard Deviation 27.32
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 244.0 Units on a scaleStandard Deviation 20.55
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 300.0 Units on a scaleStandard Deviation 0
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-8.8 Units on a scaleStandard Deviation 8.54
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 122.6 Units on a scaleStandard Deviation 15.58
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-5.5 Units on a scaleStandard Deviation 12.06
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-10.6 Units on a scaleStandard Deviation 19.11
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-2.5 Units on a scaleStandard Deviation 10.61
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 60.3 Units on a scaleStandard Deviation 8.77
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-0.9 Units on a scaleStandard Deviation 8.18
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-6.3 Units on a scaleStandard Deviation 10.41
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-4.2 Units on a scaleStandard Deviation 7.37
Ambulatory Participants With Age >=6 YearsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-3.5 Units on a scaleStandard Deviation 0.71
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 30-15.4 Units on a scaleStandard Deviation 17.61
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 12-2.9 Units on a scaleStandard Deviation 10.98
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 6-7.9 Units on a scaleStandard Deviation 21.71
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 24-17.1 Units on a scaleStandard Deviation 19.86
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 18-0.7 Units on a scaleStandard Deviation 8.13
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 12-1.6 Units on a scaleStandard Deviation 20.48
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 18-9.6 Units on a scaleStandard Deviation 10.78
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 6-1.5 Units on a scaleStandard Deviation 8.03
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 18-4.2 Units on a scaleStandard Deviation 16.02
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 12-8.8 Units on a scaleStandard Deviation 17.38
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 18-5.2 Units on a scaleStandard Deviation 7.72
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 24-5.9 Units on a scaleStandard Deviation 26.53
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Transfer and Mobility, Month 6-4.2 Units on a scaleStandard Deviation 11.53
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 12-4.0 Units on a scaleStandard Deviation 11.58
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Happiness, Month 30-2.8 Units on a scaleStandard Deviation 14.6
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 30-8.4 Units on a scaleStandard Deviation 12.32
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 30-4.7 Units on a scaleStandard Deviation 6.46
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 6-1.6 Units on a scaleStandard Deviation 17.34
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 24-15.3 Units on a scaleStandard Deviation 17.87
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 30-4.4 Units on a scaleStandard Deviation 10.81
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 124.8 Units on a scaleStandard Deviation 23.77
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 18-7.7 Units on a scaleStandard Deviation 13.52
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 6-2.1 Units on a scaleStandard Deviation 6.82
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 18-3.4 Units on a scaleStandard Deviation 18.3
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 12-4.0 Units on a scaleStandard Deviation 16.3
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Upper Extremity, Month 24-5.4 Units on a scaleStandard Deviation 11.3
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 24-4.8 Units on a scaleStandard Deviation 23.78
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Sports, Month 6-1.2 Units on a scaleStandard Deviation 13.56
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Global Function, Month 24-10.5 Units on a scaleStandard Deviation 12.07
Total Ambulatory ParticipantsChange From Baseline in PODCI Global Functioning Scale and Each Core Scale Score (Adolescent Self Report) at Months 6, 12, 18, 24 and 30Pain, Month 3010.8 Units on a scaleStandard Deviation 20.92
Secondary

Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24

EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.

Time frame: Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, some problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, some problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, no problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, some problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, no problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, no problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, some problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, no problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, some problems, Month 240 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, extreme problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, no problems, Month 240 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, extreme problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, no problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, some problems, Month 240 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, extreme problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 240 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 240 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, some problems, Month 245 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, no problems, Month 240 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 240 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, extreme problems, Month 243 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 241 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 245 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, extreme problems, Month 244 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 243 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, no problems, Month 240 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 240 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, some problems, Month 244 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 247 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, extreme problems, Month 245 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, some problems, Month 243 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, no problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, extreme problems, Month 246 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, some problems, Month 245 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, no problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 248 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, extreme problems, Month 244 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, extreme problems, Month 245 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Self-Care, some problems, Month 244 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 246 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, no problems, Month 241 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 242 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Usual Activities, no problems, Month 241 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 244 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 24Mobility, some problems, Month 244 Participants
Secondary

Number of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30

EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.

Time frame: Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. No participants were available for analysis at Month 30 in arms 'ambulatory participants with age \>=6 years' and 'total ambulatory participants' hence, 'Number of Participants Analyzed' and 'Number Analyzed' were kept 0 for these arms.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, some problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, extreme problems, Month 301 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, no problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 301 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, extreme problems, Month 301 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, no problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, no problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 301 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, extreme problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, some problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 300 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, some problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, no problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, some problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Mobility, extreme problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, no problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Self-Care, extreme problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, no problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Usual Activities, extreme problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-3L 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 300 Participants
Secondary

Number of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24

EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.

Time frame: Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 2438 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, some problems, Month 2415 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, no problems, Month 2448 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 2414 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, extreme problems, Month 240 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 2443 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, no problems, Month 2432 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 241 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, some problems, Month 2421 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, some problems, Month 2410 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 2419 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, extreme problems, Month 245 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, no problems, Month 2442 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, extreme problems, Month 2416 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, no problems, Month 2449 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, no problems, Month 2456 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, extreme problems, Month 2425 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, no problems, Month 2465 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 2452 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, some problems, Month 2460 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 242 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 2441 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, some problems, Month 2455 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 2480 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, extreme problems, Month 2423 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 242 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 2491 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, some problems, Month 2453 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, some problems, Month 2475 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, no problems, Month 24104 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, some problems, Month 2465 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, extreme problems, Month 2423 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, no problems, Month 2497 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, some problems, Month 2474 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, extreme problems, Month 2421 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, no problems, Month 2491 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, extreme problems, Month 2426 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 24118 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 2471 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 243 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 24134 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 2455 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 243 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 243 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, extreme problems, Month 2415 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 2412 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 2411 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, some problems, Month 245 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, no problems, Month 241 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, some problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 241 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, some problems, Month 243 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, no problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 240 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, no problems, Month 246 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 243 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, extreme problems, Month 246 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, extreme problems, Month 249 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, extreme problems, Month 2432 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, some problems, Month 2458 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, no problems, Month 24130 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, some problems, Month 2479 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, no problems, Month 24104 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, some problems, Month 2474 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, no problems, Month 2498 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Pain/Discomfort, extreme problems, Month 243 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, extreme problems, Month 2438 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, extreme problems, Month 244 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Anxiety/Depression, no problems, Month 24145 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Mobility, some problems, Month 2465 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, some problems, Month 2478 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Usual Activities, no problems, Month 2497 Participants
Total ParticipantsNumber of Participants According to Response to Each EQ-5D-Y 5 Dimensions at Month 24Self-Care, extreme problems, Month 2430 Participants
Secondary

Number of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12

EQ-5D-3L is a participant completed questionnaire designed to assess impact on health related quality of life. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. EQ-5D-3L assessment was only performed in participants \>= 16 years old as pre-specified in protocol.

Time frame: Months 12

Population: Full Analysis Set included all participants who had been enrolled in the study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies participants evaluable for specified rows. No ambulatory participants were \>=16 years hence N=0 in arms Ambulatory participants with aged \>=6 years and Total Ambulatory Participants.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, some problems, Month 124 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 122 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, some problems, Month 123 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 125 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, extreme problems, Month 122 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 121 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, no problems, Month 120 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 120 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, no problems, Month 121 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 125 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, extreme problems, Month 123 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 121 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, some problems, Month 123 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 120 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, no problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, no problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, some problems, Month 123 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Mobility, extreme problems, Month 123 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, no problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, some problems, Month 124 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Self-Care, extreme problems, Month 122 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, no problems, Month 121 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, some problems, Month 123 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 122 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 125 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 121 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 125 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each European Quality of Life (EuroQoL) 5 Dimension 3 Level (EQ-5D-3L) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 121 Participants
Secondary

Number of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12

EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.

Time frame: Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 1236 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 120 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, some problems, Month 1217 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, no problems, Month 1245 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 128 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, extreme problems, Month 120 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 1245 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, no problems, Month 1222 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 124 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 120 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, some problems, Month 1225 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, some problems, Month 1212 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 1221 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, extreme problems, Month 1210 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, no problems, Month 1240 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, extreme problems, Month 1217 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, no problems, Month 1270 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, no problems, Month 1291 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 1216 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, no problems, Month 1270 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 1257 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, some problems, Month 1274 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 122 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 1241 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, some problems, Month 1252 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 12101 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, extreme problems, Month 1217 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 129 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 12110 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, some problems, Month 1273 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, some problems, Month 1291 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, no problems, Month 12136 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, some problems, Month 1264 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, extreme problems, Month 1217 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, no problems, Month 1292 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, some problems, Month 1298 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, extreme problems, Month 1227 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, no problems, Month 12110 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 1216 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 12137 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 1278 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 122 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 12155 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 1249 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 1213 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 127 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, extreme problems, Month 1224 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 1217 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 1214 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, some problems, Month 127 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, no problems, Month 123 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, some problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 121 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, some problems, Month 126 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, no problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 120 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, no problems, Month 124 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 129 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 1214 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, extreme problems, Month 1214 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, extreme problems, Month 1230 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, some problems, Month 1258 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, no problems, Month 12154 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, some problems, Month 12105 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, no problems, Month 12136 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, some problems, Month 1285 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, no problems, Month 1295 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Pain/Discomfort, extreme problems, Month 122 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, extreme problems, Month 1241 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, extreme problems, Month 1214 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Anxiety/Depression, no problems, Month 12169 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Mobility, some problems, Month 1264 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, some problems, Month 1297 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Usual Activities, no problems, Month 12114 Participants
Total ParticipantsNumber of Participants According to Response to Each EuroQoL 5 Dimension Youth (EQ-5D-Y) 5 Dimensions at Month 12Self-Care, extreme problems, Month 1241 Participants
Secondary

Number of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30

EQ-5D-Y is participant completed questionnaire designed to assess impact on health related quality of life in children and adolescents \<16 years old. It is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems.

Time frame: Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, no problems, Month 3026 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 309 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, extreme problems, Month 300 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, extreme problems, Month 302 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 3018 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, some problems, Month 3010 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 3017 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, no problems, Month 3016 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 300 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, some problems, Month 300 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, no problems, Month 3016 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, extreme problems, Month 300 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, some problems, Month 308 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 300 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 308 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 3030 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, extreme problems, Month 3010 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 3048 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, no problems, Month 3028 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, no problems, Month 3034 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 304 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, some problems, Month 3034 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, some problems, Month 3040 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, extreme problems, Month 3010 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 304 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 3044 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, no problems, Month 3045 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 3026 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, extreme problems, Month 3010 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, some problems, Month 3023 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, no problems, Month 3060 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 304 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, some problems, Month 3034 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, extreme problems, Month 3010 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, no problems, Month 3061 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, some problems, Month 3031 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, extreme problems, Month 3012 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, no problems, Month 3044 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, some problems, Month 3050 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, extreme problems, Month 3010 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 3061 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 3039 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 304 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 3066 Participants
Total Ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 3034 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, no problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, extreme problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, extreme problems, Month 303 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 303 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, no problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 300 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, extreme problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 301 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, no problems, Month 303 Participants
Non-ambulatory ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, some problems, Month 302 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, extreme problems, Month 3013 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, some problems, Month 3050 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, no problems, Month 3061 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, some problems, Month 3039 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, some problems, Month 3035 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, no problems, Month 3060 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, extreme problems, Month 3010 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, extreme problems, Month 3013 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Usual Activities, no problems, Month 3047 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Self-Care, some problems, Month 3033 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, extreme problems, Month 305 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, no problems, Month 3064 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Mobility, some problems, Month 3034 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Pain/Discomfort, extreme problems, Month 304 Participants
Total ParticipantsNumber of Participants According to Response to EQ-5D-Y 5 Dimensions at Month 30Anxiety/Depression, no problems, Month 3067 Participants
Secondary

Number of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30

Number of participants with DMD mutations affecting any exon between exon 9 and exon 13 or deletion that affects both exon 29 and exon 30 is presented in this outcome measure.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Any mutation affecting any exon between exon 9 and exon 1311 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Deletion affects both exon 29 and exon 302 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Deletion affects both exon 29 and exon 306 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Any mutation affecting any exon between exon 9 and exon 1320 Participants
Total Ambulatory ParticipantsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Any mutation affecting any exon between exon 9 and exon 132 Participants
Total Ambulatory ParticipantsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Deletion affects both exon 29 and exon 301 Participants
Non-ambulatory ParticipantsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Any mutation affecting any exon between exon 9 and exon 1333 Participants
Non-ambulatory ParticipantsNumber of Participants With DMD Mutations Affecting Any Exon Between Exon 9 and Exon 13 or Deletion That Affects Both Exon 29 and Exon 30Deletion affects both exon 29 and exon 309 Participants
Secondary

Number of Participants With Each Affected Exon by Mutation Types

Number of participants with each affected exon by mutation types is presented in this outcome measure. Only those categories with non-zero values have been reported.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set with affected exon. The frequency (count) of each affected exon by mutation types was defined to be plotted for 3 groups combined, because the mutation types/affected exons were not anticipated to be varied in different age groups or by ambulation status according to available evidence globally.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 1, Exon deletion3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 2, Exon deletion3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 2, Exon duplication6 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 3, Exon deletion16 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 3, Exon duplication5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 4, Exon deletion16 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 7, Exon deletion20 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 4, Exon duplication5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 5, Exon deletion21 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 5, Exon duplication7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 5, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 6, Exon deletion20 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 6, Exon duplication8 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 6, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 6, Others1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 7, Exon duplication8 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 8, Exon deletion21 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 8, Exon duplication6 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 9, Exon deletion21 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 9, Exon duplication5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 10, Exon deletion17 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 10, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 10, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 11, Exon deletion17 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 11, Exon duplication5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 12, Exon deletion16 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 12, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 13, Exon deletion17 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 13, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 13, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 14, Exon deletion17 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 14, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 15, Exon deletion17 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 15, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 15, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 16, Exon deletion18 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 16, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 17, Exon deletion20 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 17, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 18, Exon deletion15 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 18, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 19, Exon deletion14 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 19, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 19, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 20, Exon deletion13 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 20, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 20, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 21, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 21, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 21, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 22, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 22, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 22, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 23, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 23, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 23, Point Mutation4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 24, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 24, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 24, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 24, Small insertion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 25, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 25, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 25, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 25, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 26, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 26, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 26, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 26, Small insertion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 26, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 27, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 27, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 27, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 27, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 28, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 28, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 28, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 29, Exon deletion12 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 29, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 29, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 30, Exon deletion9 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 30, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 30, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 31, Exon deletion9 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 31, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 31, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 32, Exon deletion9 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 32, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 32, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 32, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 33, Exon deletion9 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 33, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 33, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 33, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 34, Exon deletion8 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 34, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 34, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 35, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 35, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 35, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 36, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 36, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 36, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 37, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 37, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 37, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 38, Exon deletion8 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 38, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 38, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 39, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 39, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 39, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 39, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 39, Others1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 40, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 40, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 40, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 40, Small insertion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 41, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 41, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 41, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 42, Exon deletion7 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 42, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 42, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 43, Exon deletion9 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 43, Exon duplication5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 43, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 44, Exon deletion20 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 44, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 44, Point Mutation3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 44, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 45, Exon deletion42 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 45, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 46, Exon deletion73 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 46, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 46, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 47, Exon deletion73 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 47, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 47, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 47, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 48, Exon deletion83 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 48, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 48, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 48, Small insertion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 49, Exon deletion96 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 49, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 49, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 50, Exon deletion94 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 50, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 51, Exon deletion64 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 51, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 52, Exon deletion56 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 52, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 53, Exon deletion24 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 53, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 53, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 54, Exon deletion22 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 54, Exon duplication4 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 55, Exon deletion6 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 55, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 55, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 56, Exon deletion2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 56, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 56, Small deletion2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 57, Exon deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 57, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 57, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 58, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 58, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 58, Small deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 59, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 59, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 60, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 61, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 62, Exon duplication1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 62, Point Mutation2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 63, Exon deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 63, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 64, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 65, Exon deletion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 65, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 66, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 67, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 68, Exon duplication3 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 69, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 70, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 70, Point Mutation1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 71, Exon duplication2 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 72, Exon duplication1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 73, Exon duplication1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Each Affected Exon by Mutation TypesExon 74, Exon duplication1 Participants
Secondary

Number of Participants With Type of DMD Mutation

Number of participants as per type of mutation: exon deletion, exon duplication, point mutation, small insertion, small deletion and others is presented in this outcome measure. One participant could have more than 1 mutation type.

Time frame: Up to Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationExon Deletion64 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationExon Duplication10 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationPoint Mutation18 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationSmall Insertion1 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationSmall Deletion5 Participants
Ambulatory Participants With Age <6 YearsNumber of Participants With Type of DMD MutationOthers2 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationOthers1 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationSmall Insertion1 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationExon Deletion127 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationPoint Mutation21 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationExon Duplication21 Participants
Ambulatory Participants With Age >=6 YearsNumber of Participants With Type of DMD MutationSmall Deletion7 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationExon Duplication6 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationPoint Mutation8 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationSmall Insertion3 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationOthers0 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationSmall Deletion1 Participants
Total Ambulatory ParticipantsNumber of Participants With Type of DMD MutationExon Deletion18 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationSmall Deletion13 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationOthers3 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationExon Duplication37 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationSmall Insertion5 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationExon Deletion209 Participants
Non-ambulatory ParticipantsNumber of Participants With Type of DMD MutationPoint Mutation47 Participants
Secondary

Percent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 1230.9 Percentage activity impairmentStandard Deviation 26.63
Ambulatory Participants With Age <6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 3023.7 Percentage activity impairmentStandard Deviation 23.41
Ambulatory Participants With Age <6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 2441.3 Percentage activity impairmentStandard Deviation 29.38
Ambulatory Participants With Age >=6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 2451.8 Percentage activity impairmentStandard Deviation 27.98
Ambulatory Participants With Age >=6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 1248.3 Percentage activity impairmentStandard Deviation 29.02
Ambulatory Participants With Age >=6 YearsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 3056.2 Percentage activity impairmentStandard Deviation 26.49
Total Ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 2448.1 Percentage activity impairmentStandard Deviation 28.85
Total Ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 1242.5 Percentage activity impairmentStandard Deviation 29.36
Total Ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 3047.1 Percentage activity impairmentStandard Deviation 29.45
Non-ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 2462.6 Percentage activity impairmentStandard Deviation 32.78
Non-ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 1261.7 Percentage activity impairmentStandard Deviation 31.63
Non-ambulatory ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 3065.0 Percentage activity impairmentStandard Deviation 31.09
Total ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 2449.5 Percentage activity impairmentStandard Deviation 29.5
Total ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 1244.6 Percentage activity impairmentStandard Deviation 30.17
Total ParticipantsPercent Activity Impairment Score as Per WPAI: CG at Months 12, 24, and 30Month 3047.8 Percentage activity impairmentStandard Deviation 29.55
Secondary

Percent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Months 12, 24, and 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants in the Full Analysis Set and contributed data to the table; however, may not have evaluable data for every row. 'Number Analyzed' signifies participants evaluable for specified rows.

ArmMeasureGroupValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 1232.0 Percentage work impairmentStandard Deviation 25.7
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 2437.2 Percentage work impairmentStandard Deviation 27.64
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 3023.3 Percentage work impairmentStandard Deviation 24.41
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 1227.9 Percentage work impairmentStandard Deviation 23.9
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 2432.5 Percentage work impairmentStandard Deviation 24.95
Ambulatory Participants With Age <6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 3021.1 Percentage work impairmentStandard Deviation 24.23
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 2437.7 Percentage work impairmentStandard Deviation 25.92
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 3045.3 Percentage work impairmentStandard Deviation 24.6
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 1245.1 Percentage work impairmentStandard Deviation 26.4
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 3051.9 Percentage work impairmentStandard Deviation 25.52
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 1241.3 Percentage work impairmentStandard Deviation 25.01
Ambulatory Participants With Age >=6 YearsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 2444.3 Percentage work impairmentStandard Deviation 27.53
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 1236.1 Percentage work impairmentStandard Deviation 25.36
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 2435.4 Percentage work impairmentStandard Deviation 25.52
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 1239.9 Percentage work impairmentStandard Deviation 26.6
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 3040.4 Percentage work impairmentStandard Deviation 28.63
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 2441.1 Percentage work impairmentStandard Deviation 27.7
Total Ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 3035.5 Percentage work impairmentStandard Deviation 27.04
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 1240.7 Percentage work impairmentStandard Deviation 26.58
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 2445.9 Percentage work impairmentStandard Deviation 29.86
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 3056.7 Percentage work impairmentStandard Deviation 20.82
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 3056.7 Percentage work impairmentStandard Deviation 20.82
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 2441.3 Percentage work impairmentStandard Deviation 28
Non-ambulatory ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 1246.6 Percentage work impairmentStandard Deviation 29.38
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 2436.0 Percentage work impairmentStandard Deviation 25.75
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 3041.1 Percentage work impairmentStandard Deviation 28.42
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 2441.6 Percentage work impairmentStandard Deviation 27.86
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 3036.4 Percentage work impairmentStandard Deviation 27.03
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent impairment while working, Month 1236.5 Percentage work impairmentStandard Deviation 25.43
Total ParticipantsPercent Overall Work Impairment Scores as Per WPAI: CG at Months 12, 24, and 30Percent Overall Work Impairment, Month 1240.5 Percentage work impairmentStandard Deviation 26.85
Secondary

Percent Work Time Missed Score as Per WPAI: CG at Month 12

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Month 12

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 126.8 Percentage work time missedStandard Deviation 14.98
Ambulatory Participants With Age >=6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 127.3 Percentage work time missedStandard Deviation 14.11
Total Ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 127.1 Percentage work time missedStandard Deviation 14.41
Non-ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 1221.1 Percentage work time missedStandard Deviation 28.81
Total ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 128.5 Percentage work time missedStandard Deviation 16.78
Secondary

Percent Work Time Missed Score as Per WPAI: CG at Month 24

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Month 24

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 2410.5 Percentage work time missedStandard Deviation 19.7
Ambulatory Participants With Age >=6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 2413.0 Percentage work time missedStandard Deviation 23.1
Total Ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 2411.9 Percentage work time missedStandard Deviation 21.56
Non-ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 248.7 Percentage work time missedStandard Deviation 16.5
Total ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 2411.5 Percentage work time missedStandard Deviation 21.07
Secondary

Percent Work Time Missed Score as Per WPAI: CG at Month 30

WPAI:CG is a self-reported measure of work productivity and impairment, was completed by caregiver, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and activity impairment. Each score was expressed as a percentage (0-100%) with higher score indicating greater impairment and less productivity.

Time frame: Month 30

Population: Full Analysis Set included all participants who had been enrolled in the study. 'Number of Participants Analyzed' signifies all participants evaluable for this outcome measure.

ArmMeasureValue (MEAN)Dispersion
Ambulatory Participants With Age <6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 302.9 Percentage work time missedStandard Deviation 6.67
Ambulatory Participants With Age >=6 YearsPercent Work Time Missed Score as Per WPAI: CG at Month 3013.8 Percentage work time missedStandard Deviation 19.15
Total Ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 309.4 Percentage work time missedStandard Deviation 16.21
Non-ambulatory ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 300.0 Percentage work time missedStandard Deviation 0
Total ParticipantsPercent Work Time Missed Score as Per WPAI: CG at Month 309.0 Percentage work time missedStandard Deviation 15.97

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026